Organovo (ONVO) 10-K 9 Jun 15 2015 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Mar. 31, 2015	Jun. 01, 2015	Sep. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Trading Symbol	ONVO
Entity Registrant Name	ORGANOVO HOLDINGS, INC.
Entity Central Index Key	1497253
Current Fiscal Year End Date	-28
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		81,580,538
Entity Public Float			$451,713,082

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Mar. 31, 2014
Current Assets
Cash and cash equivalents	$50,142,000	$48,167,000
Inventory, net	66,000	63,000
Prepaid expenses and other current assets	1,054,000	931,000
Total current assets	51,262,000	49,161,000
Fixed assets, net	2,042,000	857,000
Restricted cash	78,800	78,800
Other assets, net	106,000	89,000
Total assets	53,489,000	50,186,000
Current Liabilities
Accounts payable	1,387,000	326,000
Accrued expenses	2,257,000	822,000
Deferred rent	759,000	345,000
Deferred revenue	227,000	13,000
Capital lease obligation	5,000	10,000
Warrant liabilities	126,000	377,000
Total current liabilities	4,761,000	1,893,000
Deferred revenue, net of current portion	32,000	4,000
Capital lease obligation, net of current portion	0	5,000
Total liabilities	4,793,000	1,902,000
Commitments and Contingencies (Note 8)
Stockholders’ Equity
Common stock, $0.001 par value; 150,000,000 shares authorized, 81,536,724 and 78,113,639 shares issued and outstanding at March 31, 2015 and March 31, 2014, respectively	82,000	78,000
Additional paid-in capital	170,909,000	140,419,000
Accumulated deficit	-122,295,000	-92,213,000
Total stockholders’ equity	48,696,000	48,284,000
Total Liabilities and Stockholders’ Equity	$53,489,000	$50,186,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Statement Of Financial Position [Abstract]
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	81,536,724	78,113,639
Common stock, shares outstanding	81,536,724	78,113,639

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012
Revenues
Product and service	$0	$0	$314	$0	$0
Collaborations	98	120	134	248	1,035
Grants	117	0	123	131	162
Total Revenues	215	120	571	379	1,197
Selling, general, and administrative expenses	2,792	902	17,947	13,054	7,080
Research and development expenses	1,448	547	12,921	7,974	3,436
Loss from Operations	-4,025	-1,329	-30,297	-20,649	-9,319
Other Income (Expense)
Fair value of warrant liabilities in excess of proceeds received	0	-19,019	0	0	-19,019
Change in fair value of warrant liabilities	-12,034	-13,506	196	-5,120	-9,931
Financing transaction costs in excess of proceeds received	0	-2,130	0	0	-2,130
Loss on inducement to exercise warrants	0	0	0	0	-1,904
Loss on disposal of fixed assets	0	0	-12	-84	-158
Interest expense	-65	-1,088	-1	-13	-1,088
Interest income	4	0	32	18	5
Other income (expense)	0	-9	0	0	-9
Total Other Income (Expense)	-12,095	-35,752	215	-5,199	-34,234
Net Loss	($16,120)	($37,081)	($30,082)	($25,848)	($43,553)
Net loss per common share—basic and diluted	($0.26)	($1.17)	($0.38)	($0.35)	($1.01)
Weighted average shares used in computing net loss per common share—basic and diluted	61,750,157	31,591,663	79,650,087	73,139,618	43,149,657

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
In Thousands, except Share data
Beginning balance at Dec. 31, 2011	($1,835)	$22	$4,835	($6,692)
Beginning balance, Shares at Dec. 31, 2011		22,445,000
Issuance of common stock in connection with the merger	0	6	-6	0
Issuance of common stock in connection with the merger, Shares		6,000,000
Issuance of common stock through private placements in connection with reverse merger	13,723	14	13,709	0
Issuance of common stock through private placements in connection with reverse merger, Shares		13,723,000
Cost associated with merger	-13,723	0	-13,723	0
Issuance of common stock through conversion of notes payable and accrued interest in connection with the merger	1,526	2	1,524	0
Issuance of common stock through conversion of notes payable and accrued interest in connection with the merger, Shares		1,525,000
Issuance of warrants to consultants	890	0	890	0
Issuance of common stock from warrant exercises, net	10,991	14	10,977	0
Issuance of common stock from warrant exercises, net, Shares		13,424,000
Warrant liability removed due to exercises of warrants	23,321	0	23,321	0
Stock option exercises	18	0	18	0
Stock option exercises, Shares		224,000
Issuance of restricted common stock	0	1	-1	0
Issuance of restricted common stock, Shares		1,380,000
Restricted stock forfeitures	0	0	0	0
Restricted stock forfeitures, Shares		-186,000
Stock-based compensation expense	1,435	0	1,435	0
Loss on inducement to exercise warrants	1,904	0	1,904	0
Net loss	-43,553	0	0	-43,553
Ending balance at Dec. 31, 2012	-5,303	59	44,883	-50,245
Ending balance, Shares at Dec. 31, 2012		58,535,000
Issuance of common stock from warrant exercises, net	3,724	6	3,718	0
Issuance of common stock from warrant exercises, net, Shares		6,131,000
Warrant liability removed due to exercises of warrants	23,869	0	23,869	0
Issuance of restricted common stock	0	0	0	0
Issuance of restricted common stock, Shares		55,000
Restricted stock forfeitures	0	0	0	0
Restricted stock forfeitures, Shares		-34,000
Stock-based compensation expense	848	0	848	0
Expense related to modification of warrants	65	0	65	0
Warrant liability reclassified to equity	1,886	0	1,886	0
Net loss	-16,120	0	0	-16,120
Ending balance at Mar. 31, 2013	8,969	65	75,269	-66,365
Ending balance, Shares at Mar. 31, 2013		64,687,000
Issuance of warrants to consultants	492	0	492	0
Issuance of common stock from warrant exercises, net	1,101	3	1,098	0
Issuance of common stock from warrant exercises, net, Shares	2,713,207	2,713,000
Warrant liability removed due to exercises of warrants	10,874	0	10,874	0
Stock option exercises	402	0	402	0
Stock option exercises, Shares	183,796	184,000
Issuance of restricted common stock	0	0	0	0
Issuance of restricted common stock, Shares		60,000
Restricted stock forfeitures	0	0	0	0
Restricted stock forfeitures, Shares		-215,000
Issuance of common stock from public offering, net	46,915	10	46,905	0
Issuance of common stock from public offering, Shares		10,684,000
Stock-based compensation expense	4,600	0	4,600	0
Expense related to modification of warrants	12	0	12	0
Warrant liability reclassified to equity	767	0	767	0
Net loss	-25,848	0	0	-25,848
Ending balance at Mar. 31, 2014	48,284	78	140,419	-92,213
Ending balance, Shares at Mar. 31, 2014		78,113,000
Issuance of warrants to consultants	316	0	316	0
Issuance of common stock from warrant exercises, net	445	0	445	0
Issuance of common stock from warrant exercises, net, Shares	210,600	211,000
Warrant liability removed due to exercises of warrants	55	0	55	0
Stock option exercises	351	0	351	0
Stock option exercises, Shares	205,684	205,000
Restricted stock forfeitures	0	0	0	0
Restricted stock forfeitures, Shares		-190,000
Issuance of common stock from public offering, net	22,307	4	22,303	0
Issuance of common stock from public offering, Shares		3,198,000
Stock-based compensation expense	7,020	0	7,020	0
Net loss	-30,082	0	0	-30,082
Ending balance at Mar. 31, 2015	$48,696	$82	$170,909	($122,295)
Ending balance, Shares at Mar. 31, 2015		81,537,000

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012
Cash Flows From Operating Activities
Net loss	($16,120,000)	($37,081,000)	($30,082,000)	($25,848,000)	($43,553,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred financing costs	0	319,000	0	0	319,000
Amortization of warrants issued for services	261,000	0	557,000	323,000	556,000
Depreciation and amortization	80,000	17,000	472,000	387,000	195,000
Loss on disposal of fixed assets	0	0	12,000	84,000	158,000
Amortization of debt discount	0	896,000	0	0	896,200
Interest accrued on convertible notes payable	0	12,000	0	0	12,000
Fair value of warrant liabilities in excess of proceeds	0	19,019,000	0	0	19,019,000
Change in fair value of warrant liabilities	12,034,000	13,506,000	-196,000	5,120,000	9,931,000
Loss on inducement to exercise warrants	0	0	0	0	1,904,000
Expense associated with warrant modification	65,000	0	0	12,000	0
Stock-based compensation	848,000	4,000	7,020,000	4,600,000	1,435,000
Increase (decrease) in cash resulting from changes in:
Grants receivable	61,000	0	0	101,000	-162,000
Inventory	0	-45,000	-3,000	25,000	-459,000
Prepaid expenses and other assets	-61,000	-65,000	-389,000	-392,000	-101,000
Accounts payable	216,000	-217,000	1,061,000	-315,000	-233,000
Accrued expenses	-283,000	-28,000	1,435,000	312,000	384,000
Deferred rent	82,000	-9,000	270,000	75,000	159,000
Deferred revenue	62,000	116,000	242,000	-45,000	-153,000
Net cash used in operating activities	-2,755,000	-3,556,000	-19,601,000	-15,561,000	-9,693,000
Cash Flows From Investing Activities
Deposits released from restriction (restricted cash deposits)	0	-38,000	0	9,000	-88,000
Purchases of fixed assets	-137,000	-6,000	-1,517,000	-277,000	-357,000
Purchases of intangible assets	-19,000	0	0	0	0
Net cash used in investing activities	-156,000	-44,000	-1,517,000	-268,000	-445,000
Cash Flows From Financing Activities
Proceeds from issuance of common stock and exercise of warrants, net	3,724,000	13,723,000	22,752,000	48,016,000	24,714,000
Proceeds from exercise of stock options	0	0	351,000	402,000	18,000
Principal payments on capital lease obligations	-2,000	0	-10,000	-10,000	-7,000
Repayment of convertible notes and interest payable	0	-110,000	0	0	-110,000
Deferred financing costs	0	0	0	-40,000	0
Net cash provided by financing activities	3,722,000	13,613,000	23,093,000	48,368,000	24,615,000
Net Increase in Cash and Cash Equivalents	811,000	10,013,000	1,975,000	32,539,000	14,477,000
Cash and Cash Equivalents at Beginning of Period	14,817,000	340,000	48,167,000	15,628,000	340,000
Cash and Cash Equivalents at End of Period	15,628,000	10,353,000	50,142,000	48,167,000	14,817,000
Supplemental Disclosure of Cash Flow Information:
Interest	0	10,000	0	0	10,000
Income Taxes	$0	$1,000	$4,000	$0	$1,000

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2012
Statement Of Cash Flows [Abstract]
Issuance of common stock to note holders			1,525,387
Convertible notes principal balance			$1,500
Accrued interest			25
Issued warrants with connection with reverse merger and private placement			32,743
Purchased equipment through capital lease			34
Transferred amount of inventory to fixed assets	272		391
Issued warrants to purchase shares of common stock for consulting services shares		75,000	650,000
Issued warrants to purchase shares of common stock for consulting services		404	890
Warrant liability reduced	23,869	10,874	23,321
Warrant reclassified as equity instruments	$1,886	$767

Change_in_Fiscal_Year_End

Change in Fiscal Year End	12 Months Ended
	Mar. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Change in Fiscal Year End	1. Change in Fiscal Year End
	On March 31, 2013, the Board of Directors of the Company (the “Board”) approved a change in the Company’s fiscal year end from December 31st to March 31st. As a result of this change, the Company filed a Transition Report on Form 10-KT for the three-month transition period ended March 31, 2013. References to any of the Company’s pre-2013 fiscal years mean the fiscal year ending December 31 of that calendar year.

Description_of_Business_and_Su

Description of Business and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Description of Business and Summary of Significant Accounting Policies	2. Description of Business and Summary of Significant Accounting Policies
	A summary of significant accounting policies, consistently applied in the preparation of the accompanying consolidated financial statements follows:
	Nature of operations and basis of presentation
	References in these notes to the consolidated financial statements to “Organovo Holdings, Inc.,” “Organovo Holdings,” “we,” “us,” “our,” “the Company” and “our Company” refer to Organovo Holdings, Inc. and its consolidated subsidiaries. Our consolidated financial statements include the accounts of the Company as well as its wholly-owned subsidiaries, with all material intercompany accounts and transactions eliminated in consolidation. In December 2014, we established a wholly-owned subsidiary, Samsara Sciences, Inc., to focus on the acquisition of qualified cells in support of our commercial and research endeavors.
	Since its inception, the Company has devoted its efforts primarily to developing and commercializing a platform technology and functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, raising capital and building infrastructure. In November 2014, the Company announced the full commercial release of its first product, the exVive3D ™ Human Liver Tissue for use in toxicology and other preclinical drug testing. As of March 31, 2015, the Company has not yet realized significant revenues from its planned principal operations. The Company’s activities are subject to significant risks and uncertainties including failing to secure additional funding to fully operationalize the Company’s current technology and continue to implement its business plan.
	Reverse merger transaction
	On February 8, 2012, Organovo, Inc., a privately held Delaware corporation, merged with and into Organovo Acquisition Corp., a wholly-owned subsidiary of Organovo Holdings, Inc., a publicly traded Delaware corporation (“the Company”), with Organovo, Inc. surviving the merger as a wholly-owned subsidiary of the Company (the “Merger”). As a result of the Merger, the Company acquired the business of Organovo, Inc., and has continued the existing business operations of Organovo, Inc.
	Simultaneously with the Merger, on February 8, 2012 (the “Closing Date”), all of the issued and outstanding shares of Organovo, Inc.’s common stock converted, on a 1 for 1 basis, into shares of the Company’s common stock, par value $0.001 per share. Also, on the closing date, all of the issued and outstanding options to purchase shares of Organovo, Inc.’s common stock and other outstanding warrants to purchase Organovo, Inc.’s common stock, and all of the issued and outstanding bridge warrants to purchase shares of Organovo, Inc.’s common stock, converted on a 1 for 1 basis, into options, warrants and new bridge warrants to purchase shares of the Company’s common stock.
	Immediately following the consummation of the Merger: (i) the former security holders of Organovo, Inc. common stock had an approximate 75% voting interest in the Company and the Company stockholders retained an approximate 25% voting interest, (ii) the former executive management team of Organovo, Inc. remained as the only continuing executive management team for the Company, and (iii) the Company’s ongoing operations consisted solely of the ongoing operations of Organovo, Inc. Based primarily on these factors, the Merger was accounted for as a reverse merger and a recapitalization in accordance with U.S. generally accepted accounting principles (“GAAP”). As a result, these financial statements reflect the historical results of Organovo, Inc. prior to the Merger, and the combined results of the Company following the Merger. The par value of Organovo, Inc. common stock immediately prior to the Merger was $0.0001 per share. The par value subsequent to the Merger is $0.001 per share, and therefore the historical results of Organovo, Inc. prior to the Merger have been retroactively adjusted to affect the change in par value.
	In connection with three separate closings of a private placement transaction completed in connection with the Merger (the “Private Placement”), the Company received gross proceeds of approximately $5.0 million, $1.8 million and $6.9 million on closings on February 8, 2012, February 29, 2012 and March 16, 2012, respectively. In 2011, the Company received $1.5 million from the purchase of 6% convertible notes which were automatically converted into 1,500,000 shares of common stock, plus 25,387 shares for accrued interest of $25,387 on the principal, on February 8, 2012.
	The cash transaction costs related to the Merger were approximately $2.1 million.
	Before the Merger, the Company’s Board of Directors and stockholders adopted the 2012 Equity Incentive Plan (the “2012 Plan”). In addition, the Company assumed and adopted Organovo, Inc.’s 2008 Equity Incentive Plan.
	NYSE MKT listing
	On July 9, 2013, the Company announced that its common stock had been approved to list on the NYSE MKT. Shares began trading on the New York Stock Exchange on July 11, 2013 under the symbol “ONVO”. Prior to that time, the Company’s shares were quoted on the OTC QX.
	Liquidity
	As of March 31, 2015, the Company had an accumulated deficit of approximately $122.3 million. The Company also had negative cash flows from operations of approximately $19.6 million during the year ended March 31, 2015.
	Through March 31, 2015, the Company has financed its operations primarily through the sale of convertible notes, the private placement of equity securities, the public offering of common stock, and through revenue derived from grants, collaborative research agreements, and product and service agreements. Based on its current operating plan and available cash resources, the Company believes it has sufficient resources to fund its business for at least the next twelve months.
	The Company will need additional capital to further fund the development and commercialization of its human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company intends to cover its future operating expenses through cash on hand, through revenue derived from research service agreements, product sales, collaborative research agreements, grants, and through the issuance of additional equity or debt securities. Depending on market conditions, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders.
	Having insufficient funds may require us to delay, scale back, or eliminate some or all of our development programs or relinquish rights to our technology on less favorable terms than we would otherwise choose. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.
	Use of estimates
	The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the consolidated financial statements include those assumed in computing the valuation of warrants and conversion features, revenue recognized under the proportional performance model, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets.
	Financial instruments
	For certain of the Company’s financial instruments, including cash and cash equivalents, inventory, prepaid expenses and other assets, accounts payable, accrued expenses, deferred revenue, and capital lease obligations, the carrying amounts are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
	Cash and cash equivalents
	The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents.
	Derivative financial instruments
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency.
	The Company reviews the terms of convertible debt and equity instruments it issues to determine whether there are derivative instruments, including an embedded conversion option that is required to be bifurcated and accounted for separately as a derivative financial instrument. In circumstances where a host instrument contains more than one embedded derivative instrument, including a conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Also, in connection with the sale of convertible debt and equity instruments, the Company may issue freestanding warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity.
	Derivative instruments are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the convertible debt or equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds allocated to the convertible host instruments are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the convertible instruments themselves, usually resulting in those instruments being recorded at a discount from their face value.
	The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method.
	Restricted cash
	As of March 31, 2015 and 2014, the Company had approximately $78,800 of restricted cash deposited with a financial institution. The entire amount is held in certificates of deposit to support a letter of credit agreement related to the Company’s facility lease.
	Inventory
	Inventories are stated at the lower of the cost or market (first-in, first-out). Inventory consists of approximately $66,000, and $63,000 in raw materials as of March 31, 2015 and 2014, respectively, net of reserves.
	Fixed assets and depreciation
	Property and equipment are carried at cost. Expenditures that extend the life of the asset are capitalized and depreciated. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the remaining lease term. The estimated useful lives of the fixed assets range between three and seven years.
	Impairment of long-lived assets
	In accordance with authoritative guidance the Company reviews its long-lived assets, including property and equipment and other assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. To determine recoverability of its long-lived assets, the Company evaluates whether future undiscounted net cash flows will be less than the carrying amount of the assets and adjusts the carrying amount of its assets to fair value. Management has determined that no impairment of long-lived assets occurred as of March 31, 2015.
	Fair value measurement
	Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
	·	Level 1 — Quoted prices in active markets for identical assets or liabilities.
	·	Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	·	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company has issued warrants, of which some are classified as derivative liabilities as a result of the terms in the warrants that provide for down-round protection in the event of a dilutive issuance. The Company uses Level 3 inputs for its valuation methodology for the warrant derivative liabilities. The estimated fair values were determined using a Monte Carlo option pricing model based on various assumptions (see Note 5). The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of derivative liabilities. Various factors are considered in the pricing models we use to value the warrants, including the Company’s current stock price, the remaining life of the warrants, the volatility of the Company’s stock price, and the risk free interest rate. Changes in these factors have had and may continue in the future to have a significant impact on the computed fair value of the warrant liability.
	The estimated fair values of the liabilities measured on a recurring basis are as follows:
			Fair Value Measurements at March 31, 2015 and 2014 (in thousands):
			Balance at			Quoted		Significant		Significant
			March 31,			Prices in		Other		Other
			2015			Active		Observable		Unobservable
						Markets		Inputs		Inputs
						(Level 1)		(Level 2)		(Level 3)
	Warrant liability		$	126		$	—	$	—	$	126
			Balance at			Quoted		Significant		Significant
			March 31,			Prices in		Other		Other
			2014			Active		Observable		Unobservable
						Markets		Inputs		Inputs
						(Level 1)		(Level 2)		(Level 3)
	Warrant liability		$	377		$	—	$	—	$	377
	The following table presents the activity for liabilities measured at estimated fair value using unobservable inputs for the years ended March 31, 2015 and 2014:
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
			Warrant
			Derivative
			Liability
			(in thousands)
Balance at March 31, 2013		$	6,898
Issuances		$	—
Adjustments to estimated fair value		$	5,120
Warrant liability removal due to settlements		$	(10,874	)
Warrant liability reclassified to equity		$	(767	)
Balance at March 31, 2014		$	377
Issuances		$	—
Adjustments to estimated fair value		$	(196	)
Warrant liability removal due to settlements		$	(55	)
Balance at March 31, 2015		$	126
Research and development
Research and development expenses, including direct and allocated expenses, consist of independent research and development costs, as well as costs associated with sponsored research and development. Research and development costs are expensed as incurred.
Income taxes
Deferred income taxes are recognized for the tax consequences in future years for differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities.
Revenue recognition
The Company’s revenues are derived from research service agreements, product sales, collaborative research agreements, and grants from the National Institute of Health (“NIH”), U.S. Treasury Department and private not-for-profit organizations.
The Company recognizes revenue when the following criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) services have been rendered or product has been delivered; (iii) price to the customer is fixed and determinable; and (iv) collection of the underlying receivable is reasonably assured.
Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of March 31, 2015 and 2014 the Company had approximately $259,000 and $17,000, respectively, in deferred revenue related to its grants, collaborative research programs and research service agreements.
Revenue arrangements with multiple deliverables
The Company periodically enters into revenue arrangements that contain multiple deliverables. Judgment is required to properly identify the accounting units of the multiple deliverable transactions and to determine the manner in which revenue should be allocated among the accounting units. Moreover, judgment is used in interpreting the commercial terms and determining when all criteria of revenue recognition have been met for each deliverable in order for revenue recognition to occur in the appropriate accounting period. For multiple deliverable agreements, consideration is allocated at the inception of the agreement to all deliverables based on their relative selling price. The relative selling price for each deliverable is determined using vendor-specific objective evidence (“VSOE”) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable.
The Company recognizes revenue for delivered elements only when it determines there are no uncertainties regarding customer acceptance. While changes in the allocation of the arrangement consideration between the units of accounting will not affect the amount of total revenue recognized for a particular sales arrangement, any material changes in these allocations could impact the timing of revenue recognition, which could affect the Company’s results of operations.
The Company expects to periodically receive license fees for non-exclusive research licensing associated with funded research projects. License fees under these arrangements are recognized over the term of the contract or development period as it has been determined that such licenses do not have stand-alone value.
Revenue from research service agreements
For research service agreements, the Company defers any up-front fees collected from customers and recognizes revenue when earned, typically when services are rendered or deliverables are provided to the customer. When substantial customer acceptance terms exist, the Company recognizes revenue for delivered elements only when it determines there are no uncertainties regarding customer acceptance.
Research and development revenue under collaborative agreements
The Company’s collaboration revenue consists of license and collaboration agreements that contain multiple elements, including non-refundable up-front fees, payments for reimbursement of third-party research costs, payments for ongoing research, payments associated with achieving specific development milestones and royalties based on specified percentages of net product sales, if any. The Company considers a variety of factors in determining the appropriate method of revenue recognition under these arrangements, such as whether the elements are separable, whether there are determinable fair values and whether there is a unique earnings process associated with each element of a contract.
The Company recognizes revenue from research funding under collaboration agreements when earned on a “proportional performance” basis as research hours are incurred. The Company performs services as specified in each respective agreement on a best-efforts basis, and is reimbursed based on labor hours incurred or achievement of milestones or certain deliverables as specified in the contract. The Company initially defers revenue for any amounts billed or payments received in advance of the services being performed, and recognizes revenue pursuant to the related pattern of performance, based on total labor hours incurred relative to total labor hours estimated under the contract.
In December 2010, the Company entered into a 12 month research contract agreement with a third party, whereby the Company was engaged to perform research and development services on a fixed-fee basis for approximately $600,000. Based on the proportional performance criteria, the Company recognized approximately $150,000 in revenue related to the contract during the year ended December 31, 2012. Total revenue recognized on the contract as of March 31, 2015 was approximately $600,000.
In October 2011, the Company entered into a research contract agreement with a third party to perform research and development services for a fixed-fee of $1,365,000. The agreement included an initial payment to the Company of approximately $239,000 with remaining payments occurring over a twenty-one month period. On November 27, 2012, the agreement was amended to include additional research and development services, for an additional $135,000, bringing the total contract value to $1,500,000. The third party ultimately elected to have only $40,000 of these additional research and development services performed by the Company, resulting in a total contract value of $1,405,000. The amendment extended the original contract (which ran concurrently) from twenty-one months to twenty-eight months. The Company recorded approximately $0, $184,000, $97,000, $120,000, and $885,000 for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012, respectively, in revenue related to the research contract in recognition of the proportional performance achieved.
In September 2013, the Company entered into a research contract agreement with a third party to perform research and development services for fixed fees ranging from approximately $7,000 to $83,000, depending on go/no-go decisions made along the way. The agreement included an initial payment to the Company of approximately $7,000 with remaining payments occurring at the completion of each phase of work. The third party ultimately elected to have $76,000 of work performed under the agreement, and as such the Company recorded approximately $69,000 and $7,000, for the years ended March 31, 2015 and 2014, respectively, in revenue related to the research contract in recognition of the proportional performance achieved.
In October 2013, the Company entered into a research contract agreement with a third party to perform research and development services for fixed fees ranging from approximately $59,000 to approximately $93,000, depending on go/no-go decisions made along the way. The agreement included an initial payment to the Company of approximately $29,000 with remaining payments occurring at the beginning of each phase of work. The third party elected to have all potential work performed under the agreement, and as such the Company recorded approximately $41,000 and $52,000, for the years ended March 31, 2015 and 2014, respectively, in revenue related to the research contract in recognition of the proportional performance achieved.
Product revenue
The Company recognizes product revenue at the time of shipment to the customer, provided all other revenue recognition criteria have been met. To date, the Company has not recognized significant revenue from commercial product sales.
As our commercial sales increase, we expect to establish a reserve for estimated product returns that will be recorded as a reduction to revenue. That reserve will be maintained to account for future return of products sold in the current period. The reserve will be reviewed quarterly and will be estimated based on an analysis of our historical experience related to product returns.
Grant revenues
During 2012, 2010 and 2009, the NIH awarded the Company three research grants totaling approximately $558,000. Revenues from these NIH grants were based upon internal and subcontractor costs incurred that were specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. These revenues were recognized when expenses had been incurred by subcontractors and as the Company incurred internal expenses that were related to the grants. Revenue recognized under these grants for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012 was approximately $0, $12,000, $117,000, $0, and $162,000, respectively.
During August of 2013, the Company was awarded a research grant by a private, not-for-profit organization for up to $251,700, contingent on go/no-go decisions made by the grantor at the completion of each stage of research as outlined in the grant award. Revenues from the grant are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized when the Company incurs expenses that are related to the grant. Revenue recognized under this grant was approximately $49,000 and $119,000 for the years ended March 31, 2015 and 2014, respectively.
During September of 2014, the NIH awarded the Company a research grant totaling approximately $222,000. The grant provides for fixed payments based on the achievement of certain milestones. As such, revenue will be recognized upon completion of those milestones. Revenue recognized under this grant was approximately $74,000 for the year ended March 31, 2015.
Stock-based compensation
The Company accounts for stock-based compensation in accordance with the Financial Accounting Standards Board’s ASC Topic 718, Compensation — Stock Compensation, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at its estimated fair value as it vests.
Comprehensive income (loss)
Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive income (loss). For the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012 the comprehensive loss was equal to the net loss.
Net loss per share
Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options, and the assumed issuance of common stock under restricted stock units, shares subject to repurchase and warrants as the effect would be anti-dilutive. No dilutive effect was calculated for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 or 2012, or the year ended December 31, 2012 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Total common stock equivalents that were excluded from computing diluted net loss per share were approximately 8.6 million, 7.7 million, 8.9 million, 25.8 million, and 15.2 million for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012 and the year ended December 31, 2012, respectively.
Reclassifications
Certain reclassifications were made to the Consolidated Balance Sheet as of March 31, 2014 in order to conform to the presentation of the Consolidated Balance Sheet as of March 31, 2015. The reclassifications did not have any effect on previously reported financial position.

Fixed_Assets

Fixed Assets	12 Months Ended
	Mar. 31, 2015
Property Plant And Equipment [Abstract]
Fixed Assets	3. Fixed Assets
	Fixed assets consisted of the following (in thousands):
		March 31,			March 31,
		2015			2014
	Laboratory equipment	$	1,951		$	1,207
	Construction in process		529			—
	Computer software and equipment		274			191
	Furniture and fixtures		135			33
	Leasehold improvements		155			—
			3,044			1,431
	Less accumulated depreciation and amortization		(1,002	)		(574	)
		$	2,042		$	857
	Depreciation and amortization expense for the years end March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012 was approximately $464,000, $380,000, $78,000, $15,000, and $188,000, respectively.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Mar. 31, 2015
Payables And Accruals [Abstract]
Accrued Expenses	4. Accrued Expenses
	Accrued expenses consisted of the following (in thousands):
		March 31,		March 31,
		2015		2014
	Accrued compensation	$	1,917	$	505
	Accrued legal and professional fees		195		283
	Other accrued expenses		145		34
		$	2,257	$	822

Derivative_Liability

Derivative Liability	12 Months Ended
	Mar. 31, 2015
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Liability	5. Derivative Liability
	During 2012, in relation to the reverse Merger and the three offerings under the Private Placement, the Company issued 21,347,182 five-year warrants to purchase the Company’s common stock. In October and November of 2011, the Company issued 1,500,000 five-year warrants in connection with Convertible Notes. The exercise price of the warrants is protected against down-round financing throughout the term of the warrant, as described below. Pursuant to ASC 815-15 and ASC 815-40, the fair value of the warrants of approximately $32.7 million and $1.3 million in 2012 and 2011, respectively, was recorded as a derivative liability on the issuance dates.
	The Company revalued the warrants as of the end of each reporting period, and the estimated fair value of the outstanding warrant liabilities was $0.1 million, $0.4 million, $6.9 million, and $20.6 million as of March 31, 2015, March 31, 2014, March 31, 2013, and December 31, 2012, respectively. The change in fair value of the derivative liabilities for the year ended March 31, 2015 was a decrease of $0.2 million. The changes in fair value of the derivative liabilities for the year ended March 31, 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012 were increases of $5.1 million, $12.0 million, $13.5 million, and $9.9 million, respectively. These changes are included in other income (expense) in the statements of operations.
	During the years ended March 31, 2015 and 2014, 8,647 and 1,920,874 warrants that were classified as derivative liabilities were exercised. The warrants were revalued as of the settlement date, and the change in fair value was recognized to earnings. In addition, in the year ended March 31, 2014 the Company entered into amendment agreements with certain of the warrant holders, which removed the down-round pricing protection provision, resulting in 269,657 of these warrants being reclassified from liability instruments to equity instruments. The Company also recognized a reduction in the warrant liability based on the fair value as of the settlement date for the warrants exercised and as of the modification date for the warrants that were amended, with a corresponding increase in additional paid-in capital.
	The derivative liabilities were valued at the closing dates of the Private Placement and the end of each reporting period using a Monte Carlo valuation model with the following assumptions:
		March 31,			March 31,
		2015			2014
	Closing price per share of common stock	$	3.54		$	7.64
	Exercise price per share	$	1		$	1
	Expected volatility		76.8	%		76.5	%
	Risk-free interest rate		0.56	%		0.9	%
	Dividend yield		—			—
	Remaining expected term of underlying securities (years)		1.96			2.96
	In addition, as of the valuation dates, management assessed the probabilities of future financings assumptions in the Monte Carlo valuation models. Management also applied a discount for lack of marketability to the valuation of the derivative liabilities based on such trading restrictions due to certain of the shares not being registered.
	In accordance with the terms of the warrant agreements, if, prior to the expiration date of the warrants, the Company issues additional shares of common stock, as defined below, without consideration or for a consideration per share less than the exercise price of the warrants in effect immediately prior to such issue, then the exercise price shall be reduced, concurrently with such issue, to a price (calculated to the nearest cent) determined by multiplying such exercise price by a fraction, (A) the numerator of which shall be (1) the number of shares of common stock outstanding immediately prior to such issue plus (2) the number of shares of common stock which the aggregate consideration received or to be received by the Company for the total number of additional shares of common stock so issued would purchase at such exercise price; and (B) the denominator of which shall be the number of shares of common stock outstanding immediately prior to such issue plus the number of such additional shares of common stock so issued; provided that (i) all shares of common stock issuable upon conversion or exchange of convertible securities outstanding immediately prior to such issue shall be deemed to be outstanding, and (ii) the number of shares of common stock deemed issuable upon conversion or exchange of such outstanding convertible securities shall be determined without giving effect to any adjustments to the conversion or exchange price or conversion or exchange rate of such convertible securities resulting from the issuance of additional shares of common stock that is the subject of this calculation. For purposes of the warrants, “additional shares of common stock” shall mean all shares of common stock issued by the Company after the effective date (including without limitation any shares of common stock issuable upon conversion or exchange of any convertible securities or upon exercise of any option or warrant, on an as-converted basis), other than: (i) shares of common stock (and/or warrants for any class of equity securities of the Company) issued or issuable upon conversion or exchange of any convertible securities or exercise of any options or warrants outstanding on the effective date; (ii) shares of common stock issued or issuable by reason of a dividend, stock split, split-up or other distribution on shares of common stock; (iii) shares of common stock (or options with respect thereto) issued or issuable to employees or directors of, or consultants to, the Company or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors of the Company; (iv) any securities issued or issuable by the Company pursuant to (A) the Private Placement; or (B) the Merger; (v) securities issued pursuant to acquisitions or strategic transactions approved by a majority of disinterested directors of the Company, provided that any such issuance shall only be to a person which is, itself or through its subsidiaries, an operating company in a business synergistic with the business of the Company and in which the Company receives benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities and (vi) securities issued to financial institutions, institutional investors or lessors in connection with credit arrangements, equipment financings or similar transactions approved by a majority of disinterested directors of the Company, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.
	Upon each adjustment of the exercise price pursuant to the provisions stated above, the number of warrant shares issuable upon exercise of the warrants shall be adjusted by multiplying a number equal to the exercise price in effect immediately prior to such adjustment by the number of warrant shares issuable upon exercise of the warrant immediately prior to such adjustment and dividing the product so obtained by the adjusted exercise price.

Convertible_Notes_Payable

Convertible Notes Payable	12 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Convertible Notes Payable	6. Convertible Notes Payable
	Local bridge
	During July and August 2011, $740,000 of Convertible Notes bearing interest at 20% per annum, and warrants to purchase shares of common stock were issued to investors. The Convertible Notes were due at the earlier of 1) one year from the issuance date or 2) one week after the consummation of a Merger transaction. The number of warrants to be issued was equal to the note principal divided by the exercise price. The exercise price was the per-share or per-unit fair market value received in the Merger. The notes were convertible at a price per share equal to seventy-five percent (75%) of the per-share fair market value of the total consideration received for a share of a public company’s common stock to be determined to be identified upon consummation of a merger.
	The Company determined that the beneficial conversion feature and the warrants did not represent embedded derivative instruments. Additionally, at issuance of the Convertible Notes, the Company did not record the discount for the beneficial conversion feature due to the contingencies surrounding conversion. The beneficial conversion feature was recorded when the contingencies were resolved. In accordance with ASC 470-20, Debt with Conversion and Other Options, the Company recorded a discount of approximately $583,700 for the warrants in 2011. The discount was amortized to interest expense over the term of the Convertible Notes using the effective interest method.
	Exchange Agreement and Release
	In October 2011, the Company’s Board of Directors and stockholders approved an Exchange Agreement and Release, whereby the note holders could exchange their Convertible Notes and accrued interest for shares of the Company’s common stock and warrants to purchase the Company’s common stock. A total of $3,030,000 of principal and approximately $459,800 of accrued interest converted, at prices ranging from $0.27 to $0.75, into 7,676,828 shares of the Company’s common stock, plus five-year warrants to purchase 1,309,750 common shares at an exercise price of $1.00 per share. For the holders that elected to participate, the Exchange Agreement and Release resulted in the cancellation of the Convertible Notes and release from the note holders for any claims related to the Convertible Notes.
	The Company determined that the warrants issued in connection with the Exchange Agreement and Release did not represent derivative instruments. The warrants, valued at approximately $527,600, were classified as equity instruments and recorded as interest expense on the date of issuance in 2011. The Company calculated the fair value of the warrants using the Black-Scholes Model, using a volatility of 110.13%, an interest rate of 1.11% and a dividend yield of zero.
	At December 31, 2011, an unsecured $100,000 Convertible Note, with interest at 10% and a maturity date of April 2014, remained outstanding. In February 2012, at the close of the Merger, the convertible note and accrued interest in the aggregate of approximately $110,000 were repaid.
	2011 Private Placement
	On September 18, 2011, Organovo, Inc.’s Board of Directors authorized a Private Placement offering of up to 30 units of its securities at a price of $50,000 per unit for an aggregate purchase price of $1,500,000. Each unit consisted of a convertible note in the principal amount of $50,000 accruing simple interest at the rate of 6% per annum (the “Convertible Notes”), plus five-year warrants to purchase 50,000 shares of the next Qualified Round of Equity Securities, at an exercise price of $1.00 per share. The principal plus accrued interest was convertible into the Company’s common stock upon consummation of a Merger transaction.
	During October and November 2011, $1,500,000 of Convertible Notes bearing interest at 6% per annum with a maturity date of March 30, 2012, and five-year warrants to purchase 1,500,000 shares of the Company’s common stock were issued to investors under the Private Placement. The warrants are exercisable at $1.00 per share, expire in five years, and contain down-round price protection. The Convertible Notes were outstanding at December 31, 2011, and were converted into 1,525,387 units during February 2012, in connection with the Merger.
	The Company determined that the warrants represent a derivative instrument due to the down-round price protection, and accordingly, the Company recorded a derivative liability related to the warrants, with a corresponding debt discount of approximately $1,260,300. See Note 5. Additionally, upon issuance of the notes during 2011, the Company recorded the discount for the beneficial conversion feature of $239,700. The debt discount associated with the warrants and beneficial conversion feature were amortized to interest expense over the life of the Convertible Notes, and fully amortized upon conversion of the Convertible Notes in 2012. The Company recorded approximately $896,200 of interest expense for the amortization of the debt discount during the year ended December 31, 2012.
	As consideration for locating investors to participate in the Private Placement, the placement agent earned a cash payment of $195,000 in 2011. Additionally, upon closing of the Merger transaction in 2012, the placement agent earned five-year warrants to purchase 610,155 shares of the Company’s common stock at $1.00 per share. These warrants contain down round protection and were classified as derivative liabilities upon issuance. See Note 5.
	2012 Private Placement
	During 2012, concurrently with the closing of the Merger and in contemplation of the Merger, the Company completed the initial closing of the Private Placement of up to 8,000,000 units of its securities, at a price of $1.00 per unit, with the ability to increase the offering to an aggregate of up to 16,000,000 units. Each unit consisted of one share of common stock and a warrant to purchase one share of common stock. The Company completed three closings under the Private Placement during 2012, and raised total gross proceeds of $13,722,600 and total net proceeds of $11,593,066. The Company issued 13,722,600 shares of its common stock and warrants to purchase 15,247,987 shares of its common stock (including warrants to purchase 1,525,387 shares to former holders of the Convertible Notes) exercisable at $1.00 to investors in the offering. The placement agent and its selected dealers were paid total cash commissions of $1,372,260 and the placement agent was paid an expense allowance of $411,678 and was issued placement agent warrants to purchase 6,099,195 shares of the Company’s common stock at an exercise price of $1.00 per share.
	The warrants issued to the investors and the placement agent, as described above, contain down round protection, and accordingly, were classified as derivative liabilities upon issuance. On the closing date, the derivative liabilities were recorded at an estimated fair value of approximately $32,742,000. Given that the fair value of the derivative liabilities exceeded the total proceeds of the private placement of $13,722,600, no net amounts were allocated to the common stock. The amount by which the recorded liabilities exceeded the proceeds of approximately $19,019,400 was charged to other expense at the closing dates. The Company has revalued the derivative liability as of each reporting period, and will continue to do so on each subsequent balance sheet date until the securities to which the derivative liabilities relate are exercised or expire, with any changes in the fair value recognized through earnings in the statement of operations. See Note 5.
	Interest expense, including amortization of the note discounts and other interest expense was approximately $1,000, $13,000, $65,000, $1,088,000, and $1,088,000 for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012, respectively.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity
	Common stock
	A shelf registration statement on Form S-3 (File No. 333-189995), or shelf, was filed with the SEC on July 17, 2013 authorizing the offer and sale in one or more offerings of up to $100,000,000 in aggregate of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities. This shelf was declared effective by the SEC on July 26, 2013.
	On August 2, 2013, the Company, entered into an Underwriting Agreement (the “Underwriting Agreement”) with Lazard Capital Markets LLC, acting as representative of the underwriters named in the Underwriting Agreement (the “Underwriters”) and joint book-runner with Oppenheimer & Co. Inc., relating to the issuance and sale of 10,350,000 shares of the Company’s common stock, which includes the issuance and sale of 1,350,000 shares pursuant to an overallotment option exercised by the Underwriters on August 5, 2013. JMP Securities LLC and Maxim Group LLC each acted as co-managers for the offering. The price to the public in the offering was $4.50 per share, and the Underwriters purchased the shares from the Company pursuant to the Underwriting Agreement at a price of $4.23 per share. The net proceeds to the Company from the offering were approximately $43.4 million, after deducting underwriting discounts and commissions and other offering expenses of $3.2 million payable by the Company, including the Underwriters’ exercise of the overallotment option. The transactions contemplated by the Underwriting Agreement closed on August 7, 2013.
	In November 2013, the Company entered into an equity distribution agreement with an investment banking firm. Under the terms of the distribution agreement, the Company may offer and sell up to 4,000,000 shares of its common stock, from time to time, through the investment bank in at-the-market (“ATM”) offerings, as defined by the SEC, and pursuant to the Company’s effective shelf registration statement previously filed with the SEC. During the years ended March 31, 2015 and 2014, the Company issued 2,197,768 and 334,412 shares of common stock in ATM offerings under the distribution agreement with net proceeds of $16.1 and $3.5 million, respectively.
	In December 2014, the Company entered into an equity offering sales agreement with another investment banking firm. Under the terms of the sales agreement, the Company may offer and sell shares of its common stock, from time to time, through the investment bank in ATM offerings, as defined by the SEC, and pursuant to the Company’s effective shelf registration statement previously filed with the SEC. During the year ended March 31, 2015, the Company sold 1,000,000 shares of common stock in ATM offerings under the sales agreement with net proceeds of $6.2 million. The Company intends to use the net proceeds raised through any ATM sales for general corporate purposes, including research and development, the commercialization of the Company’s products, general administrative expenses, and working capital and capital expenditures.
	The Company will limit future sales under the 2013 distribution agreement and the 2014 sales agreement to ensure that it does not exceed the maximum amount available for sale under its effective shelf registration statement previously filed with the SEC. Based on its use of the shelf registration statement through March 31, 2015, the Company cannot sell more than an aggregate of $26,777,785 in shares of common stock under the 2013 distribution agreement and the 2014 sales agreement.
	A shelf registration statement on Form S-3 (File No. 333-202382), or shelf, was filed with the SEC on February 27, 2015 authorizing the offer and sale in one or more offerings of up to $190,000,000 in aggregate of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities. This shelf was declared effective by the SEC on March 17, 2015.
	In addition, during the years ended March 31, 2015 and 2014, the Company issued 210,600 and 2,713,207 shares of common stock upon exercise of 211,647 and 3,201,633 warrants, respectively.
	During the years ended March 31, 2015 and 2014, the Company issued 205,033 and 183,796 shares of common stock upon exercise of 205,684 and 183,796 options, respectively.
	Restricted stock awards
	In May of 2008, the Board of Directors of the Company approved the 2008 Equity Incentive Plan (the “2008 Plan”). The 2008 Plan authorized the issuance of up to 1,521,584 common shares for awards of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock award units, and stock appreciation rights. The 2008 Plan terminates on July 1, 2018. No shares have been issued under the 2008 Plan since 2011, and the Company does not intend to issue any additional shares from the 2008 Plan in the future.
	In January 2012, the Board of Directors of the Company approved the 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan authorized the issuance of up to 6,553,986 shares of common stock for awards of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance units, performance shares, and other stock or cash awards. The Board of Directors and stockholders of the Company approved an amendment to the 2012 Plan in August 2013 to increase the number of shares of common stock that may be issued under the 2012 Plan by 5,000,000 shares, for an aggregate of 11,553,986 shares issuable under the 2012 Plan. The 2012 Plan terminates ten years after its adoption.
	On August 6, 2012, 200,000 restricted stock awards were issued to a member of senior management, the vesting of which was performance based with achievement to be measured at December 31, 2014 or earlier if the metric was achieved. As of December 31, 2014, the Company had determined that three of the four target metrics had been achieved with the fourth performance metric criterion not met resulting in 150,000 shares of restricted stock vested and the remaining 50,000 restricted stock awards surrendered back to the Company unvested. The Company recognized the related stock-based compensation expense over the requisite service period ending on March 31, 2015.
	During the year ended December 31, 2012, the Company issued an aggregate 950,000 of restricted stock awards to certain members of senior management and 130,000 restricted stock awards to non-executive employees. The vesting schedule is 25% on each anniversary of the vesting start date over four years. Additionally, the Company issued 100,000 restricted stock awards to a consultant. The vesting schedule is 100% after 6 months.
	During the year ended December 31, 2012, there were 95,842 restricted stock awards forfeited by staff members upon termination of their employment with the Company. Additionally, 89,674 restricted stock awards were surrendered related to shares of common stock returned to the Company, at the option of the holders, to cover the tax liability related to the vesting of 211,250 restricted stock awards. Upon the return of the common stock, 89,674 stock option grants with immediate vesting were granted to the individuals at the vesting date market value strike price.
	During the three months ended March 31, 2013, the Company issued an aggregate of 55,000 restricted stock awards with immediate vesting to a consultant.
	During the three months ended March 31, 2013, there were 10,000 restricted stock awards forfeited by one staff member upon termination of their employment with the Company. Additionally, 24,690 restricted stock awards were surrendered related to shares of common stock returned to the Company, at the option of the holder, to cover the tax liability related to the vesting of 50,000 restricted stock awards. Upon the return of the common stock, 24,690 stock option grants with immediate vesting were granted to the individual at the vesting date market value strike price.
	During the year ended March 31, 2014, 218,655 restricted stock awards were surrendered related to shares of common stock returned to the Company, at the option of the holder, to cover the tax liability related to the vesting of 405,000 restricted stock awards. Upon the return of the common stock, 218,655 stock option grants with immediate vesting were granted to the individual at the vesting date market value strike price.
	During the year ended March 31, 2014, the Company issued an aggregate of 60,000 restricted stock units with immediate vesting to a consultant.
	During the year ended March 31, 2015, 137,816 restricted stock awards were surrendered related to shares of common stock returned to the Company, at the option of the holder, to cover the tax liability related to the vesting of 255,000 restricted stock awards. Upon the return of the common stock, 137,816 stock option grants with immediate vesting were granted to the individual at the vesting date market value strike price.
	A summary of the Company’s restricted stock award activity is as follows:
		Number of
		Shares
	Unvested at December 31, 2011		1,111,295
	Granted		1,380,000
	Vested		(1,233,409	)
	Canceled / forfeited		(95,842	)
	Unvested at December 31, 2012		1,162,044
	Granted		55,000
	Vested		(221,302	)
	Canceled / forfeited		(10,000	)
	Unvested at March 31, 2013		985,742
	Granted		60,000
	Vested		(472,247	)
	Canceled / forfeited		—
	Unvested at March 31, 2014		573,495
	Granted		—
	Vested		(262,245	)
	Canceled / forfeited		(52,500	)
	Unvested at March 31, 2015		258,750
	The fair value of each restricted common stock award is recognized as stock-based compensation expense over the vesting term of the award. The Company recorded restricted stock-based compensation expense in operating expenses for employees and non-employees of approximately $421,000, $817,000, $478,000, $0, and $835,000, during the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012, respectively. Expense for each of the periods included approximately $15,000, $16,000, $4,000, $0, and $23,000, for research and development during the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012, respectively. General and administrative expense for the years ended March 31, 2015 and March 31, 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012 were approximately $406,000, $801,000, $474,000, $0, and $812,000, respectively.
	As of March 31, 2015, total unrecognized restricted stock-based compensation expense was approximately $222,000, which will be recognized over a weighted average period of 0.62 years.
	Stock options
	During the years ended March 31, 2015 and 2014, under the 2012 Equity Incentive Plan, 1,429,191 and 2,519,572 incentive stock options were issued, respectively, at various exercise prices. The stock options generally vest on the one year anniversary of the grant date, quarterly over a three year period, or over a four-year period, with a quarter vesting on either the one year anniversary of employment or the one year anniversary of the vesting commencement date, and the remainder vesting ratably over the remaining 36 month terms with the exception of 139,316 and 218,655 of the incentive stock option grants during the years ended March 31, 2015 and 2014, respectively, that have immediate vesting at the grant date, 56,500 and 99,500 of the incentive stock option grants in the years ended March 31, 2015 and 2014, respectively, that vest quarterly over three years, and 128,500 and 122,500 of the incentive stock option grants in the years ended March 31, 2015 and 2014, respectively, that vest after one full year.
	The following table summarizes stock option activity for the years ended March 31, 2014 and 2015:
		Options			Weighted-			Aggregate
		Outstanding			Average			Intrinsic
					Exercise Price			Value
	Outstanding at March 31, 2013		3,618,567		$	2.11		$	5,909,154
	Options granted		2,519,572		$	8.63
	Options canceled		(18,455	)	$	3.31
	Options exercised		(183,796	)	$	2.19		$	1,002,419
	Outstanding at March 31, 2014		5,935,888		$	4.87		$	20,482,823
	Options granted		1,429,191		$	6.18
	Options canceled		(45,847	)	$	7.17
	Options exercised		(205,684	)	$	1.73		$	883,795
	Outstanding at March 31, 2015		7,113,548		$	5.21		$	4,969,499
	Vested and Exercisable at March 31, 2015		3,113,164		$	4.05		$	3,264,723
	The weighted-average remaining contractual term of options exercisable and outstanding at March 31, 2015 was approximately 7.82 years and 8.28 years, respectively.
	The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:
		Year Ended			Year Ended
		31-Mar-15			31-Mar-14
	Dividend yield		—			—
Volatility		76.9	%		78.22	%
Risk-free interest rate		1.6	%		1.32	%
Expected life of options	6.00 years			6.00 years
Weighted average grant date fair value	$	4.14		$	5.92
The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Due to the Company’s limited historical data, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. Certain options granted to consultants are subject to variable accounting treatment and are required to be revalued until vested.
The total stock option based compensation recorded as operating expense was approximately $6,599,000, $3,783,000, $370,000, $4,000, and $600,000, for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012, respectively. Expense included approximately $1,175,000, $462,000, $58,000 and $81,000 for research and development during the years ended March 31, 2015 and 2014, the three months ended March 31, 2013, and the year ended December 31, 2012, respectively. General and administrative expense for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and year ended December 31, 2012, were approximately $5,424,000, $3,321,000, $312,000, $4,000, and $519,000, respectively.
The total unrecognized compensation cost related to unvested stock option grants as of March 31, 2015 was approximately $15,115,000 and the weighted average period over which these grants are expected to vest is 2.77 years.
Warrants
During the years ended December 31, 2012 and 2011, the Company issued warrants to investors to purchase 21,347,182 and 2,909,750 shares, respectively, of its common stock.
During the years ended March 31, 2015 and 2014, 203,000 and 225,000 of these warrants were exercised for cash proceeds of approximately $445,000 and $210,000, respectively, and 8,647 and 2,628,003 of these warrants were exercised through a cashless exercise for issuance of 7,600 and 2,139,577 shares of common stock, respectively.
In December 2012, the Company consummated a warrant tender offer to the holders of outstanding warrants to purchase approximately 14.5 million shares of the Company’s common stock. In accordance with the tender offer, for those warrant holders that elected to participate, this resulted in a reduction of the exercise price of the warrants from $1.00 per share to $0.80 per share of common stock in cash, shortened the exercise period of the warrants so that they expired concurrently with the tender offer, and removed the price-based anti-dilution provisions contained in the warrants. The Company completed the tender offer on December 21, 2012, resulting in approximately 9.6 million warrants being exercised for gross proceeds of approximately $7,700,000. In connection with the transaction, the Company recognized an expense for the inducement to exercise the warrants of approximately $1,900,000. The Company also incurred approximately $400,000 in placement agent fees, legal costs, and other related fees, which have been recognized as an offset to the proceeds received from the warrant exercises.
During the year ended March 31, 2014, derivative liability warrants of 1,920,874 were exercised and 6,990,556 of the warrants exercised during the three months ended March 31, 2013 and 13,010,237 of the warrants exercised in 2012 were derivative liabilities and were valued at the settlement date. The warrant liability was reduced to equity at the fair value on the settlement date. See Note 5.
During the twelve months ended March 31, 2014, the Company entered into amendment agreements for 269,657 warrants to purchase common stock which reduced the exercise price of the warrants from $1.00 to $0.85, which removed the down-round price protection provision of the warrant agreement related to the adjustment of exercise price upon issuance of additional shares of common stock. As a result of the removal of the down-round price protection provision, the warrants were reclassified from liability to equity instruments at their fair value. The Company determined the incremental expense associated with the modification based on the fair value of the awards prior to and subsequent to the modification. The fair value of the awards subsequent to modification was calculated using the Black-Scholes model. The incremental expense associated with the modification of approximately $12,000 was recognized as interest expense for the year ended March 31, 2014.
During the year ended December 31, 2012 the Company entered into four agreements with consultants for services. In connection with the agreements, the Company issued a total of 650,000 warrants to purchase common stock, at prices ranging from $1.70 to $3.24, with lives ranging from two to five years, to be earned over service periods of up to six months. The fair value of the warrants was estimated to be approximately $890,000, which was recognized as a prepaid asset and is being amortized over the term of the consulting agreements. These warrants were classified as equity instruments because they do not contain any anti-dilution provisions. The Black-Scholes model, using volatility rates ranging from 79.8% to 103.8% and risk free interest rate factors ranging from 0.24% to 0.63%, were used to determine the value. The value is being amortized over the term of the agreements. During the years ended March 31, 2015 and 2014, the Company recognized approximately $0 and $72,000, respectively, of expense related to these services. During the year ended March 31, 2015, no warrants held by consultants were exercised. During the year ended March 31, 2014, 348,630 warrants held by consultants were exercised resulting in proceeds to the Company of approximately $891,000.
During November 2013 the Company entered into an agreement with a consultant for services. In connection with the agreement, the Company issued 75,000 warrants to purchase common stock, at a price of $7.36, with a life of five years, to be earned over a twelve month service period. The fair value of the warrants was estimated to be approximately $404,000, which was recognized as a prepaid asset and is being amortized over the term of the consulting agreement. These warrants were classified as equity instruments because they do not contain any anti-dilution provisions. The Black-Scholes model, using a volatility rate of 96.90% and a risk-free interest rate factor of 0.60%, was used to determine the value. The Company recognized approximately $43,000 and $163,000 during the years ended March 31, 2015 and 2014, respectively, related to these services.
Additionally, during September 2014, the Company issued 50,000 warrants to a consultant in recognition of services previously provided. These warrants were classified as equity instruments because they do not contain any anti-dilution provisions. The Company recognized approximately $237,000 during the year ended March 31, 2015 related to these services.
During November 2014 the Company entered into an agreement with a consultant for services. In connection with the agreement, the Company issued 145,000 warrants to purchase common stock, at a price of $6.84, with a life of five years, to be earned over a seventeen month service period ending on March 31, 2016. The final number of vested warrant shares will be determined, at the discretion of management, based on management’s judgment of the satisfaction of specific performance metrics prior to the earliest to occur of March 31, 2016 or the termination of the consulting arrangement with the Company. The initial fair value of the warrants was estimated to be approximately $309,000, which is being revalued and amortized over the term of the consulting agreement. These warrants were classified as equity instruments because they do not contain any anti-dilution provisions. The Black-Scholes model, using a volatility rate of 76.78% and a risk-free interest rate factor of 1.37%, was used to determine the value. The Company recognized approximately $36,000 during the year ended March 31, 2015 related to these services.
The following table summarizes warrant activity for the years ended March 31, 2015 and 2014:
	Warrants			Weighted-Average
				Exercise Price
Balance at March 31, 2013		4,283,889		$	1.17
Granted		112,500		$	7.36
Expired / Canceled		—			—
Exercised		(3,201,633	)	$	1.16
Balance at March 31, 2014		1,194,756		$	1.79
Granted		195,000		$	7.04
Expired / Canceled		—			—
Exercised		(211,647	)	$	2.14
Balance at March 31, 2015		1,178,109		$	2.59
The warrants outstanding at March 31, 2015 are immediately exercisable at prices between $0.85 and $7.36 per share, and have a weighted average remaining term of approximately 2.38 years.
Common stock reserved for future issuance
Common stock reserved for future issuance consisted of the following at March 31, 2015:
Common stock warrants outstanding		1,178,109
Common stock options outstanding under the 2008 Plan		622,192
Common stock options outstanding and reserved under the 2012		9,375,272
Plan
Total		11,175,573
Preferred stock
The Company is authorized to issue 25,000,000 shares of preferred stock. There are no shares of preferred stock currently outstanding, and the Company has no present plans to issue shares of preferred stock.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies
	Operating leases
	The Company leases office and laboratory space under a non-cancelable operating lease entered into in February 2012 and amended in December 2013 and March 2015, and a non-cancelable operating lease entered into on January 9, 2015 with the future minimum lease payments from the leases included below. The Company records rent expense on a straight-line basis over the life of the leases and records the excess of expense over the amounts paid as deferred rent. In addition, one of the leases provides for certain improvements made for the Company’s benefit to be funded by the landlord. Such costs, totaling approximately $144,000 to date, have been capitalized as fixed assets and included in deferred rent.
	Rent expense was approximately $968,000, $561,500, $105,500, $60,200, and $325,600 for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012, respectively.
	On February 27, 2012, the Company entered into a facilities lease at 6275 Nancy Ridge Drive (the “Original Lease”), San Diego, CA 92121, with occupancy as of July 15, 2012. The base rent under the lease was approximately $38,800 per month with 3% annual escalators. The lease term was 48 months with an option for the Company to extend the lease at the end of the lease term.
	On December 5, 2013, the Company entered into a First Amendment (the “First Amendment”) to the Original Lease, together with the First Amendment, (the “Amended Lease”). Pursuant to the First Amendment, the Company expanded the size of its facility by approximately 15,268 square feet (the “Expansion Premises”) from approximately 15,539 square feet (the “Original Premises”) for a total of approximately 30,807 square feet. The Amended Lease provides for base rent (i) on the Original Premises to continue at approximately $38,800 per month, with annual escalators, until August 1, 2016, at which point the base rent shall be payable at the same rate per rentable square foot as the Expansion Premises and (ii) on the Expansion Premises of approximately $38,934 per month, with 3% annual escalators, not to commence until two months after the earlier of (A) the date that the landlord delivers possession of the Expansion Premises to the Company with the work in the Expansion Lab Premises (as defined in the First Amendment) substantially complete and (B) the date the landlord could have delivered the Expansion Premises with the work in the Expansion Lab Premises (as defined in the First Amendment) substantially complete but for certain delays of the Company. Additionally, the Company has a right of first refusal on adjacent additional premises of approximately 14,500 square feet. The term of the Amended Lease expires on the seven-year anniversary of the earlier of (A) the date that the landlord delivers possession of the Expansion Premises to the Company and (B) the date the landlord could have delivered the Expansion Premises but for certain delays of the Company (the “Expansion Premises Commencement Date”). The Expansion Premises Commencement Date was September 1, 2014. The Company also has the option to terminate the Amended Lease on the 5-year anniversary of the Expansion Premises Commencement Date. The Expansion Premises contains office, laboratory, and clean room areas.
	On March 12, 2015, the Company entered into a Second Amendment to the Original Lease (the “Second Amendment), to adjust the square footage covered by Amended Lease and an additional portion of the building containing approximately 335 rentable square feet (“Second Expansion Premises”). This square footage adjustment was the result of the re-measurement of each suite and the building overall. The net adjustment to overall leased space was an increase of 88 square feet with a corresponding increase in monthly rental payments at the same rate per square foot as the Expansion Premises.
	On January 9, 2015, the Company entered into an agreement to lease a second facility consisting of 5,803 rentable square feet of office and lab space located at 6310 Nancy Ridge Drive, San Diego, CA 92121. The term of the lease is 36 months, beginning on February 1, 2015 and ending on January 31, 2018, with monthly rental payments of approximately $12,000 commencing on April 1, 2015. In addition, there are annual rent escalations of 3.0% on each 12-month anniversary of the lease commencement date.
	Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of March 31, 2015, are as follows (in thousands):
	Fiscal year ended March 31, 2016	$	1,138
	Fiscal year ended March 31, 2017		1,148
	Fiscal year ended March 31, 2018		1,134
	Fiscal year ended March 31, 2019		1,032
	Fiscal year ended March 31, 2020		1,062
	Thereafter		1,558
	Total	$	7,072
	Legal matters
	In addition to commitments and obligations in the ordinary course of business, the Company is subject to various claims and pending and potential legal actions arising out of the normal conduct of its business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against it may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability.
	The Company regularly reviews contingencies to determine the adequacy of its accruals and related disclosures. During the period presented, the Company has not recorded any accrual for loss contingencies associated with such claims or legal proceedings; determined that an unfavorable outcome is probable or reasonably possible; or determined that the amount or range of any possible loss is reasonably estimable. However, the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against the Company in a reporting period, the Company’s consolidated financial statements for that reporting period could be materially adversely affected.
	Spencer Trask Matter. In June 2013, the Company filed a declaratory relief action against Spencer Trask Ventures (“STV”) in the Supreme Court of New York (case #652305/2013) following claims by STV that it was entitled to additional compensation arising from a warrant tender offer the Company completed in December 2012. The Company is seeking a declaration that a Warrant Solicitation Agency Agreement (the “WSAA”) between the parties is a valid and enforceable agreement; the Company believes that under the terms of this agreement and the Placement Agent Agreement (the “PAA”) it entered into with STV in connection with the private placement financings the Company completed in February and March 2012, STV is not entitled to the additional compensation it is seeking.
	Also in June, 2013, STV initiated an arbitration in which it is alleging (1) breach of contract, and (2) breach of confidentiality obligations under the terms of the PAA. STV is seeking compensation (including a cash fee and warrants to purchase common stock) as a result of the Company’s warrant tender offer in December 2012 and its warrant redemption in 2013, and damages for breach of confidentiality provisions in relation to the contacting of warrant holders who participated in the warrant tender offer. The Company believes there was no breach of confidentiality, as the Company’s tender offer was made to warrant holders of record relating to warrants already owned by them and whose identity was public information via a Registration Statement on Form S-1 the Company was required to file to register the resale of the shares underlying their warrants.
	In January 2014, the Supreme Court of New York stayed the New York litigation, finding that the arbitrator should determine in the first instance which disputes between the Company and STV should proceed in the Arbitration and which disputes between the Company and STV should proceed in the New York Court. The parties are proceeding in the Arbitration and the Company has reserved its right to file a summary disposition motion with regard to the proper venue for its claims under the WSAA. The date for the Arbitration (previously scheduled for July, 2015) has been taken off the calendar but may be rescheduled for the fall of 2015. The Company believes that the assertions made against it by STV are without merit and the Company intends to continue to vigorously defend against the claims made by STV.

Licensing_Agreements_and_Resea

Licensing Agreements and Research Contracts	12 Months Ended
	Mar. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Licensing Agreements and Research Contracts	9. Licensing Agreements and Research Contracts
	University of Missouri
	On March 24, 2009, the Company entered into a license agreement with the Curators of the University of Missouri to in-license certain technology and intellectual property relating to self-assembling cell aggregates and to intermediate cellular units. The Company received the exclusive worldwide rights to commercialize products comprising this technology for all fields of use. The Company paid to the University of Missouri a nonrefundable license fee of $25,000 and has committed to reimburse the University of Missouri for certain prior and future patent costs. Each year the Company is required to pay the University of Missouri royalties ranging from 1% to 3% of net sales depending on the level of net sales achieved by the Company each year. A minimum annual royalty of $25,000 is due beginning two years after the calendar year of the first commercial sale and is credited to sales royalties. The license agreement terminates upon expiration of the patents licensed and is subject to certain conditions as defined in the license agreement, which are expected to expire after 2029. The $25,000 license fee is included in Other Assets in the accompanying balance sheets and is being amortized over the life of the related patent.
	On March 12, 2010, the Company entered into a license agreement with the Curators of the University of Missouri to in-license certain technology and intellectual property relating to engineered biological nerve grafts. The Company received the exclusive worldwide rights to commercialize products comprising this technology for all fields of use. The Company paid to the University of Missouri a nonrefundable license fee of $5,000 and has committed to reimburse the University of Missouri for certain prior and future patent costs. In 2012, the Company paid the University of Missouri approximately $193,500 for prior patent costs relating to the license agreements with the University of Missouri. No payments were made during the years ended March 31, 2015, March 31, 2014 or the three months ended March 31, 2013. Each year the Company is required to pay the University of Missouri royalties ranging from 1% to 3% of net sales depending on the level of net sales achieved by the Company each year. A minimum annual royalty of $5,000 is due beginning two years after the calendar year of the first commercial sale and is credited to sales royalties. The license agreement terminates upon expiration of the patents licensed and is subject to certain conditions as defined in the license agreement. The $5,000 license fee is included in Other Assets and is being amortized over the life of the related patent.
	Clemson University
	On May 2, 2011, the Company entered into a license agreement with Clemson University Research Foundation to in-license certain technology and intellectual property relating to ink-jet printing of viable cells. The Company received the exclusive worldwide rights to commercialize products comprising this technology for all fields of use. The Company agreed to pay Clemson University a nonrefundable license fee of $32,500, as well as an additional $32,500 to reimburse Clemson University for certain prior and future patent costs. These fees, totaling $65,000, are included in Other Assets and are being amortized over the life of the related patent. Each year the Company is required to pay the University royalties ranging from 1.5% to 3% of net sales depending on the level of net sales reached each year and minimum annual fees ranging from $20,000 to $40,000. Specific terms of the royalty and license agreements are confidential. The license agreement terminates upon expiration of the patents licensed, which is expected to expire in May 2024, and is subject to certain conditions as defined in the license agreement. Annual royalty payments of $20,000 were due beginning in calendar 2014, and as of March 31, 2015, the Company has made $40,000 of royalty payments under this license agreement.
	Becton Dickinson
	In February of 2013, the Company purchased the exclusive rights to intellectual property relating to perfusion bioreactors for culturing cells from Becton Dickinson and Company for $18,500. This fee is included in Other Assets and is being amortized over the life of the related patent. This patent represents the acquisition of bioreactor technology for the support of our 3D tissues for use in drug discovery and development. No future royalties or milestone payments are owed to Becton Dickinson and Company for this patent.
	Capitalized license fees consisted of the following (in thousands):
		March 31,			March 31,
		2015			2014
	License fees	$	114		$	114
	Less accumulated amortization		(34	)		(25	)
	License fees, net	$	80		$	89
	Amortization expense of licenses was approximately $8,500, $8,500, $2,000, $1,700, and $7,000 for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, the year ended December 31, 2012. At March 31, 2015, the weighted average remaining amortization period for all licenses was approximately 10 years. The annual amortization expense of licenses for the next five years is estimated to be approximately $8,500 per year.

Income_Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets are as follows as of March 31, 2015 and 2014 (in thousands):
		March 31,			March 31,
		2015			2014
	Deferred tax assets:
	Net operating loss carry forwards	$	—		$	—
	Research and development credits		—			—
	Depreciation and amortization		(48	)		22
	Accrued expenses and reserves		826			280
	Stock compensation		3,462			1,941
	Other, net		6			1
	Total deferred tax assets		4,246			2,244
	Valuation allowance		(4,246	)		(2,244	)
		$	—		$	—
	A full valuation allowance has been established to offset the deferred tax assets as management cannot conclude that realization of such assets is more likely than not. Under the Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of our net operating loss and research tax credit carryforwards to offset taxable income may be limited based on cumulative changes in ownership. We have not completed an analysis to determine whether any such limitations have been triggered as of March 31, 2015. Until this analysis is completed, we have removed the deferred tax assets related to net operating losses and research credits from our deferred tax asset schedule. Further, until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Due to the existence of the valuation allowance, future changes in the Company’s unrecognized tax benefits will not impact its effective tax rate. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. The valuation allowance increased by approximately $2,002,000 and $1,277,000 for the years ended March 31, 2015 and 2014, respectively.
	The Company had federal and state net operating loss carryforwards of approximately $59,334,000 and $58,850,000 at March 31, 2015, respectively. The federal and state net operating loss carryforwards will begin expiring in 2028, unless previously utilized. The net operating loss carryforwards included approximately $6,236,000 of windfall tax benefits related to stock compensation that will be recorded as an increase to additional paid in capital.
	The Company had federal and state research tax credit carry forwards of approximately $790,000 and $987,000 at March 31, 2015, respectively. The federal research tax credit carryforwards begin expiring in 2028. The state research tax credit carryforwards do not expire.
	In 2009 the Company adopted the accounting guidance for uncertainty in income taxes pursuant to ASC 740-10. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. The Company did not record any accruals for income tax accounting uncertainties for the year ended March 31, 2015.
	The Company’s policy is to recognize interest and penalties that would be assessed in relation to the settlement value of unrecognized tax benefits as a component of income tax expense. The Company did not accrue either interest or penalties from inception through March 31, 2015.
	The Company does not have any unrecognized tax benefits that will significantly decrease or increase within 12 months of March 31, 2015.
	The Company is subject to tax in the United States and in the state of California. As of March 31, 2015, the Company’s tax years from inception are subject to examination by the tax authorities. The Company is not currently under examination by any U.S. federal or state jurisdictions.

Concentrations

Concentrations	12 Months Ended
	Mar. 31, 2015
Risks And Uncertainties [Abstract]
Concentrations	11. Concentrations
	Credit risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company has not experienced losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

Defined_Benefit_Plan

Defined Benefit Plan	12 Months Ended
	Mar. 31, 2015
Defined Benefit Pension Plans And Defined Benefit Postretirement Plans Disclosure [Abstract]
Defined Benefit Plan	12. Defined Benefit Plan
	The Company has a defined contribution 401(k) plan covering substantially all employees. During the year ended March 31, 2015, the 401(k) plan was amended (“the Amended Plan”) to include an employer matching provision. Under the terms of the Amended Plan, the Company will make matching contributions on up to the first 6 % of compensation contributed by its employees. Amounts expensed under the Company’s 401(k) plan for the years ended March 31, 2015 and 2014 were approximately $57,000 and $0, respectively.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	12 Months Ended
	Mar. 31, 2015
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Pronouncements	13. Recent Accounting Pronouncements
	In May 2014, the Financial Accountings Standards Board issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for us on April 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting.
	In June 2014, the FASB issued ASU 2014-10, Development Stage Entities, which eliminated certain financial reporting requirements under Topic 915 for entities considered to be in the development stage. This standard becomes effective for annual reporting periods beginning after December 15, 2014 and interim reporting periods beginning after December 15, 2015, with earlier application permitted. The Company adopted this standard prospectively as of April 1, 2014. This adoption had no effect on current or previously reported amounts, but eliminated the need to present inception-to-date financial information that was previously required under Topic 915.
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern—Disclosures of Uncertainties about an entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 provides new guidance related to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards and to provide related footnote disclosures. This new guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The requirements of ASU 2014-15 are not expected to have a significant impact on our consolidated financial statements.

Subsequent_Events

Subsequent Events	12 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events
	On April 17, 2015, the Company entered into a multi-year research collaboration agreement with Merck Sharp & Dohme Corp. (“Merck”). The Agreement will give Merck access to Organovo’s commercial exVive3DTM Human Liver Tissue service, and will also involve a collaboration to develop multiple custom tissue models utilizing the Company’s proprietary NovoGen Bioprinting PlatformTM for use in drug development.

Description_of_Business_and_Su1

Description of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Nature of Operations and Basis of Presentation	Nature of operations and basis of presentation
	References in these notes to the consolidated financial statements to “Organovo Holdings, Inc.,” “Organovo Holdings,” “we,” “us,” “our,” “the Company” and “our Company” refer to Organovo Holdings, Inc. and its consolidated subsidiaries. Our consolidated financial statements include the accounts of the Company as well as its wholly-owned subsidiaries, with all material intercompany accounts and transactions eliminated in consolidation. In December 2014, we established a wholly-owned subsidiary, Samsara Sciences, Inc., to focus on the acquisition of qualified cells in support of our commercial and research endeavors.
	Since its inception, the Company has devoted its efforts primarily to developing and commercializing a platform technology and functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, raising capital and building infrastructure. In November 2014, the Company announced the full commercial release of its first product, the exVive3D ™ Human Liver Tissue for use in toxicology and other preclinical drug testing. As of March 31, 2015, the Company has not yet realized significant revenues from its planned principal operations. The Company’s activities are subject to significant risks and uncertainties including failing to secure additional funding to fully operationalize the Company’s current technology and continue to implement its business plan.
Reverse merger transaction	Reverse merger transaction
	On February 8, 2012, Organovo, Inc., a privately held Delaware corporation, merged with and into Organovo Acquisition Corp., a wholly-owned subsidiary of Organovo Holdings, Inc., a publicly traded Delaware corporation (“the Company”), with Organovo, Inc. surviving the merger as a wholly-owned subsidiary of the Company (the “Merger”). As a result of the Merger, the Company acquired the business of Organovo, Inc., and has continued the existing business operations of Organovo, Inc.
	Simultaneously with the Merger, on February 8, 2012 (the “Closing Date”), all of the issued and outstanding shares of Organovo, Inc.’s common stock converted, on a 1 for 1 basis, into shares of the Company’s common stock, par value $0.001 per share. Also, on the closing date, all of the issued and outstanding options to purchase shares of Organovo, Inc.’s common stock and other outstanding warrants to purchase Organovo, Inc.’s common stock, and all of the issued and outstanding bridge warrants to purchase shares of Organovo, Inc.’s common stock, converted on a 1 for 1 basis, into options, warrants and new bridge warrants to purchase shares of the Company’s common stock.
	Immediately following the consummation of the Merger: (i) the former security holders of Organovo, Inc. common stock had an approximate 75% voting interest in the Company and the Company stockholders retained an approximate 25% voting interest, (ii) the former executive management team of Organovo, Inc. remained as the only continuing executive management team for the Company, and (iii) the Company’s ongoing operations consisted solely of the ongoing operations of Organovo, Inc. Based primarily on these factors, the Merger was accounted for as a reverse merger and a recapitalization in accordance with U.S. generally accepted accounting principles (“GAAP”). As a result, these financial statements reflect the historical results of Organovo, Inc. prior to the Merger, and the combined results of the Company following the Merger. The par value of Organovo, Inc. common stock immediately prior to the Merger was $0.0001 per share. The par value subsequent to the Merger is $0.001 per share, and therefore the historical results of Organovo, Inc. prior to the Merger have been retroactively adjusted to affect the change in par value.
	In connection with three separate closings of a private placement transaction completed in connection with the Merger (the “Private Placement”), the Company received gross proceeds of approximately $5.0 million, $1.8 million and $6.9 million on closings on February 8, 2012, February 29, 2012 and March 16, 2012, respectively. In 2011, the Company received $1.5 million from the purchase of 6% convertible notes which were automatically converted into 1,500,000 shares of common stock, plus 25,387 shares for accrued interest of $25,387 on the principal, on February 8, 2012.
	The cash transaction costs related to the Merger were approximately $2.1 million.
	Before the Merger, the Company’s Board of Directors and stockholders adopted the 2012 Equity Incentive Plan (the “2012 Plan”). In addition, the Company assumed and adopted Organovo, Inc.’s 2008 Equity Incentive Plan.
Liquidity	Liquidity
	As of March 31, 2015, the Company had an accumulated deficit of approximately $122.3 million. The Company also had negative cash flows from operations of approximately $19.6 million during the year ended March 31, 2015.
	Through March 31, 2015, the Company has financed its operations primarily through the sale of convertible notes, the private placement of equity securities, the public offering of common stock, and through revenue derived from grants, collaborative research agreements, and product and service agreements. Based on its current operating plan and available cash resources, the Company believes it has sufficient resources to fund its business for at least the next twelve months.
	The Company will need additional capital to further fund the development and commercialization of its human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company intends to cover its future operating expenses through cash on hand, through revenue derived from research service agreements, product sales, collaborative research agreements, grants, and through the issuance of additional equity or debt securities. Depending on market conditions, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders.
	Having insufficient funds may require us to delay, scale back, or eliminate some or all of our development programs or relinquish rights to our technology on less favorable terms than we would otherwise choose. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.
Use of estimates	Use of estimates
	The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the consolidated financial statements include those assumed in computing the valuation of warrants and conversion features, revenue recognized under the proportional performance model, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets.
Financial instruments	Financial instruments
	For certain of the Company’s financial instruments, including cash and cash equivalents, inventory, prepaid expenses and other assets, accounts payable, accrued expenses, deferred revenue, and capital lease obligations, the carrying amounts are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
Cash and cash equivalents	Cash and cash equivalents
	The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents.
Derivative financial instruments	Derivative financial instruments
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency.
	The Company reviews the terms of convertible debt and equity instruments it issues to determine whether there are derivative instruments, including an embedded conversion option that is required to be bifurcated and accounted for separately as a derivative financial instrument. In circumstances where a host instrument contains more than one embedded derivative instrument, including a conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Also, in connection with the sale of convertible debt and equity instruments, the Company may issue freestanding warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity.
	Derivative instruments are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the convertible debt or equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds allocated to the convertible host instruments are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the convertible instruments themselves, usually resulting in those instruments being recorded at a discount from their face value.
	The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method.
Restricted cash	Restricted cash
	As of March 31, 2015 and 2014, the Company had approximately $78,800 of restricted cash deposited with a financial institution. The entire amount is held in certificates of deposit to support a letter of credit agreement related to the Company’s facility lease.
Inventory	Inventory
	Inventories are stated at the lower of the cost or market (first-in, first-out). Inventory consists of approximately $66,000, and $63,000 in raw materials as of March 31, 2015 and 2014, respectively, net of reserves.
Fixed assets and depreciation	Fixed assets and depreciation
	Property and equipment are carried at cost. Expenditures that extend the life of the asset are capitalized and depreciated. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the remaining lease term. The estimated useful lives of the fixed assets range between three and seven years.
Impairment of long-lived assets	Impairment of long-lived assets
	In accordance with authoritative guidance the Company reviews its long-lived assets, including property and equipment and other assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. To determine recoverability of its long-lived assets, the Company evaluates whether future undiscounted net cash flows will be less than the carrying amount of the assets and adjusts the carrying amount of its assets to fair value. Management has determined that no impairment of long-lived assets occurred as of March 31, 2015.
Fair value measurement	Fair value measurement
	Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
	·	Level 1 — Quoted prices in active markets for identical assets or liabilities.
	·	Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	·	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company has issued warrants, of which some are classified as derivative liabilities as a result of the terms in the warrants that provide for down-round protection in the event of a dilutive issuance. The Company uses Level 3 inputs for its valuation methodology for the warrant derivative liabilities. The estimated fair values were determined using a Monte Carlo option pricing model based on various assumptions (see Note 5). The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of derivative liabilities. Various factors are considered in the pricing models we use to value the warrants, including the Company’s current stock price, the remaining life of the warrants, the volatility of the Company’s stock price, and the risk free interest rate. Changes in these factors have had and may continue in the future to have a significant impact on the computed fair value of the warrant liability.
	The estimated fair values of the liabilities measured on a recurring basis are as follows:
			Fair Value Measurements at March 31, 2015 and 2014 (in thousands):
			Balance at			Quoted		Significant		Significant
			March 31,			Prices in		Other		Other
			2015			Active		Observable		Unobservable
						Markets		Inputs		Inputs
						(Level 1)		(Level 2)		(Level 3)
	Warrant liability		$	126		$	—	$	—	$	126
			Balance at			Quoted		Significant		Significant
			March 31,			Prices in		Other		Other
			2014			Active		Observable		Unobservable
						Markets		Inputs		Inputs
						(Level 1)		(Level 2)		(Level 3)
	Warrant liability		$	377		$	—	$	—	$	377
	The following table presents the activity for liabilities measured at estimated fair value using unobservable inputs for the years ended March 31, 2015 and 2014:
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
			Warrant
			Derivative
			Liability
			(in thousands)
	Balance at March 31, 2013		$	6,898
	Issuances		$	—
	Adjustments to estimated fair value		$	5,120
	Warrant liability removal due to settlements		$	(10,874	)
	Warrant liability reclassified to equity		$	(767	)
	Balance at March 31, 2014		$	377
	Issuances		$	—
	Adjustments to estimated fair value		$	(196	)
	Warrant liability removal due to settlements		$	(55	)
	Balance at March 31, 2015		$	126
Research and development	Research and development
	Research and development expenses, including direct and allocated expenses, consist of independent research and development costs, as well as costs associated with sponsored research and development. Research and development costs are expensed as incurred.
Income taxes	Income taxes
	Deferred income taxes are recognized for the tax consequences in future years for differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities.
Revenue recognition	Revenue recognition
	The Company’s revenues are derived from research service agreements, product sales, collaborative research agreements, and grants from the National Institute of Health (“NIH”), U.S. Treasury Department and private not-for-profit organizations.
	The Company recognizes revenue when the following criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) services have been rendered or product has been delivered; (iii) price to the customer is fixed and determinable; and (iv) collection of the underlying receivable is reasonably assured.
	Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of March 31, 2015 and 2014 the Company had approximately $259,000 and $17,000, respectively, in deferred revenue related to its grants, collaborative research programs and research service agreements.
Revenue arrangements with multiple deliverables	Revenue arrangements with multiple deliverables
	The Company periodically enters into revenue arrangements that contain multiple deliverables. Judgment is required to properly identify the accounting units of the multiple deliverable transactions and to determine the manner in which revenue should be allocated among the accounting units. Moreover, judgment is used in interpreting the commercial terms and determining when all criteria of revenue recognition have been met for each deliverable in order for revenue recognition to occur in the appropriate accounting period. For multiple deliverable agreements, consideration is allocated at the inception of the agreement to all deliverables based on their relative selling price. The relative selling price for each deliverable is determined using vendor-specific objective evidence (“VSOE”) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable.
	The Company recognizes revenue for delivered elements only when it determines there are no uncertainties regarding customer acceptance. While changes in the allocation of the arrangement consideration between the units of accounting will not affect the amount of total revenue recognized for a particular sales arrangement, any material changes in these allocations could impact the timing of revenue recognition, which could affect the Company’s results of operations.
	The Company expects to periodically receive license fees for non-exclusive research licensing associated with funded research projects. License fees under these arrangements are recognized over the term of the contract or development period as it has been determined that such licenses do not have stand-alone value.
Revenue from research service agreements	Revenue from research service agreements
	For research service agreements, the Company defers any up-front fees collected from customers and recognizes revenue when earned, typically when services are rendered or deliverables are provided to the customer. When substantial customer acceptance terms exist, the Company recognizes revenue for delivered elements only when it determines there are no uncertainties regarding customer acceptance.
Research and development revenue under collaborative agreements	Research and development revenue under collaborative agreements
	The Company’s collaboration revenue consists of license and collaboration agreements that contain multiple elements, including non-refundable up-front fees, payments for reimbursement of third-party research costs, payments for ongoing research, payments associated with achieving specific development milestones and royalties based on specified percentages of net product sales, if any. The Company considers a variety of factors in determining the appropriate method of revenue recognition under these arrangements, such as whether the elements are separable, whether there are determinable fair values and whether there is a unique earnings process associated with each element of a contract.
	The Company recognizes revenue from research funding under collaboration agreements when earned on a “proportional performance” basis as research hours are incurred. The Company performs services as specified in each respective agreement on a best-efforts basis, and is reimbursed based on labor hours incurred or achievement of milestones or certain deliverables as specified in the contract. The Company initially defers revenue for any amounts billed or payments received in advance of the services being performed, and recognizes revenue pursuant to the related pattern of performance, based on total labor hours incurred relative to total labor hours estimated under the contract.
	In December 2010, the Company entered into a 12 month research contract agreement with a third party, whereby the Company was engaged to perform research and development services on a fixed-fee basis for approximately $600,000. Based on the proportional performance criteria, the Company recognized approximately $150,000 in revenue related to the contract during the year ended December 31, 2012. Total revenue recognized on the contract as of March 31, 2015 was approximately $600,000.
	In October 2011, the Company entered into a research contract agreement with a third party to perform research and development services for a fixed-fee of $1,365,000. The agreement included an initial payment to the Company of approximately $239,000 with remaining payments occurring over a twenty-one month period. On November 27, 2012, the agreement was amended to include additional research and development services, for an additional $135,000, bringing the total contract value to $1,500,000. The third party ultimately elected to have only $40,000 of these additional research and development services performed by the Company, resulting in a total contract value of $1,405,000. The amendment extended the original contract (which ran concurrently) from twenty-one months to twenty-eight months. The Company recorded approximately $0, $184,000, $97,000, $120,000, and $885,000 for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012, respectively, in revenue related to the research contract in recognition of the proportional performance achieved.
	In September 2013, the Company entered into a research contract agreement with a third party to perform research and development services for fixed fees ranging from approximately $7,000 to $83,000, depending on go/no-go decisions made along the way. The agreement included an initial payment to the Company of approximately $7,000 with remaining payments occurring at the completion of each phase of work. The third party ultimately elected to have $76,000 of work performed under the agreement, and as such the Company recorded approximately $69,000 and $7,000, for the years ended March 31, 2015 and 2014, respectively, in revenue related to the research contract in recognition of the proportional performance achieved.
	In October 2013, the Company entered into a research contract agreement with a third party to perform research and development services for fixed fees ranging from approximately $59,000 to approximately $93,000, depending on go/no-go decisions made along the way. The agreement included an initial payment to the Company of approximately $29,000 with remaining payments occurring at the beginning of each phase of work. The third party elected to have all potential work performed under the agreement, and as such the Company recorded approximately $41,000 and $52,000, for the years ended March 31, 2015 and 2014, respectively, in revenue related to the research contract in recognition of the proportional performance achieved.
Product revenue	Product revenue
	The Company recognizes product revenue at the time of shipment to the customer, provided all other revenue recognition criteria have been met. To date, the Company has not recognized significant revenue from commercial product sales.
	As our commercial sales increase, we expect to establish a reserve for estimated product returns that will be recorded as a reduction to revenue. That reserve will be maintained to account for future return of products sold in the current period. The reserve will be reviewed quarterly and will be estimated based on an analysis of our historical experience related to product returns.
Grant revenues	Grant revenues
	During 2012, 2010 and 2009, the NIH awarded the Company three research grants totaling approximately $558,000. Revenues from these NIH grants were based upon internal and subcontractor costs incurred that were specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. These revenues were recognized when expenses had been incurred by subcontractors and as the Company incurred internal expenses that were related to the grants. Revenue recognized under these grants for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012 was approximately $0, $12,000, $117,000, $0, and $162,000, respectively.
	During August of 2013, the Company was awarded a research grant by a private, not-for-profit organization for up to $251,700, contingent on go/no-go decisions made by the grantor at the completion of each stage of research as outlined in the grant award. Revenues from the grant are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized when the Company incurs expenses that are related to the grant. Revenue recognized under this grant was approximately $49,000 and $119,000 for the years ended March 31, 2015 and 2014, respectively.
	During September of 2014, the NIH awarded the Company a research grant totaling approximately $222,000. The grant provides for fixed payments based on the achievement of certain milestones. As such, revenue will be recognized upon completion of those milestones. Revenue recognized under this grant was approximately $74,000 for the year ended March 31, 2015.
Stock-based compensation	Stock-based compensation
	The Company accounts for stock-based compensation in accordance with the Financial Accounting Standards Board’s ASC Topic 718, Compensation — Stock Compensation, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
	The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at its estimated fair value as it vests.
Comprehensive income (loss)	Comprehensive income (loss)
	Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive income (loss). For the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012, and the year ended December 31, 2012 the comprehensive loss was equal to the net loss.
Net loss per share	Net loss per share
	Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options, and the assumed issuance of common stock under restricted stock units, shares subject to repurchase and warrants as the effect would be anti-dilutive. No dilutive effect was calculated for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 or 2012, or the year ended December 31, 2012 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Total common stock equivalents that were excluded from computing diluted net loss per share were approximately 8.6 million, 7.7 million, 8.9 million, 25.8 million, and 15.2 million for the years ended March 31, 2015 and 2014, the three months ended March 31, 2013 and 2012 and the year ended December 31, 2012, respectively.
Reclassifications	Reclassifications
	Certain reclassifications were made to the Consolidated Balance Sheet as of March 31, 2014 in order to conform to the presentation of the Consolidated Balance Sheet as of March 31, 2015. The reclassifications did not have any effect on previously reported financial position.

Description_of_Business_and_Su2

Description of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Estimated Fair Values of Liabilities Measured on Recurring Basis	The estimated fair values of the liabilities measured on a recurring basis are as follows:
		Fair Value Measurements at March 31, 2015 and 2014 (in thousands):
		Balance at			Quoted		Significant		Significant
		March 31,			Prices in		Other		Other
		2015			Active		Observable		Unobservable
					Markets		Inputs		Inputs
					(Level 1)		(Level 2)		(Level 3)
	Warrant liability	$	126		$	—	$	—	$	126
		Balance at			Quoted		Significant		Significant
		March 31,			Prices in		Other		Other
		2014			Active		Observable		Unobservable
					Markets		Inputs		Inputs
					(Level 1)		(Level 2)		(Level 3)
	Warrant liability	$	377		$	—	$	—	$	377
Activity for Liabilities Measured at Estimated Fair Value Using Unobservable Inputs	The following table presents the activity for liabilities measured at estimated fair value using unobservable inputs for the years ended March 31, 2015 and 2014:
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
		Warrant
		Derivative
		Liability
		(in thousands)
	Balance at March 31, 2013	$	6,898
	Issuances	$	—
	Adjustments to estimated fair value	$	5,120
	Warrant liability removal due to settlements	$	(10,874	)
	Warrant liability reclassified to equity	$	(767	)
	Balance at March 31, 2014	$	377
	Issuances	$	—
	Adjustments to estimated fair value	$	(196	)
	Warrant liability removal due to settlements	$	(55	)
	Balance at March 31, 2015	$	126

Fixed_Assets_Tables

Fixed Assets (Tables)	12 Months Ended
	Mar. 31, 2015
Property Plant And Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consisted of the following (in thousands):
		March 31,			March 31,
		2015			2014
	Laboratory equipment	$	1,951		$	1,207
	Construction in process		529			—
	Computer software and equipment		274			191
	Furniture and fixtures		135			33
	Leasehold improvements		155			—
			3,044			1,431
	Less accumulated depreciation and amortization		(1,002	)		(574	)
		$	2,042		$	857

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Mar. 31, 2015
Payables And Accruals [Abstract]
Summary of Accrued Expenses	Accrued expenses consisted of the following (in thousands):
		March 31,		March 31,
		2015		2014
	Accrued compensation	$	1,917	$	505
	Accrued legal and professional fees		195		283
	Other accrued expenses		145		34
		$	2,257	$	822

Derivative_Liability_Tables

Derivative Liability (Tables)	12 Months Ended
	Mar. 31, 2015
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Assumptions Used to Value Derivative Liabilities at End of Each Reporting Period	The derivative liabilities were valued at the closing dates of the Private Placement and the end of each reporting period using a Monte Carlo valuation model with the following assumptions:
		March 31,			March 31,
		2015			2014
	Closing price per share of common stock	$	3.54		$	7.64
	Exercise price per share	$	1		$	1
	Expected volatility		76.8	%		76.5	%
	Risk-free interest rate		0.56	%		0.9	%
	Dividend yield		—			—
	Remaining expected term of underlying securities (years)		1.96			2.96

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Summary of Company's Restricted Stock Award Activity	A summary of the Company’s restricted stock award activity is as follows:
		Number of
		Shares
	Unvested at December 31, 2011		1,111,295
	Granted		1,380,000
	Vested		(1,233,409	)
	Canceled / forfeited		(95,842	)
	Unvested at December 31, 2012		1,162,044
	Granted		55,000
	Vested		(221,302	)
	Canceled / forfeited		(10,000	)
	Unvested at March 31, 2013		985,742
	Granted		60,000
	Vested		(472,247	)
	Canceled / forfeited		—
	Unvested at March 31, 2014		573,495
	Granted		—
	Vested		(262,245	)
	Canceled / forfeited		(52,500	)
	Unvested at March 31, 2015		258,750
Summary of Stock Option Activity	The following table summarizes stock option activity for the years ended March 31, 2014 and 2015:
		Options			Weighted-			Aggregate
		Outstanding			Average			Intrinsic
					Exercise Price			Value
	Outstanding at March 31, 2013		3,618,567		$	2.11		$	5,909,154
	Options granted		2,519,572		$	8.63
	Options canceled		(18,455	)	$	3.31
	Options exercised		(183,796	)	$	2.19		$	1,002,419
	Outstanding at March 31, 2014		5,935,888		$	4.87		$	20,482,823
	Options granted		1,429,191		$	6.18
	Options canceled		(45,847	)	$	7.17
	Options exercised		(205,684	)	$	1.73		$	883,795
	Outstanding at March 31, 2015		7,113,548		$	5.21		$	4,969,499
	Vested and Exercisable at March 31, 2015		3,113,164		$	4.05		$	3,264,723
Fair Value of Employee Stock Options	The fair value of stock options was estimated at the grant date using the following weighted average assumptions:
		Year Ended			Year Ended
		31-Mar-15			31-Mar-14
	Dividend yield		—			—
	Volatility		76.9	%		78.22	%
	Risk-free interest rate		1.6	%		1.32	%
	Expected life of options	6.00 years			6.00 years
	Weighted average grant date fair value	$	4.14		$	5.92
Summary of Warrant Activity	The following table summarizes warrant activity for the years ended March 31, 2015 and 2014:
		Warrants			Weighted-Average
					Exercise Price
	Balance at March 31, 2013		4,283,889		$	1.17
	Granted		112,500		$	7.36
	Expired / Canceled		—			—
	Exercised		(3,201,633	)	$	1.16
	Balance at March 31, 2014		1,194,756		$	1.79
	Granted		195,000		$	7.04
	Expired / Canceled		—			—
	Exercised		(211,647	)	$	2.14
	Balance at March 31, 2015		1,178,109		$	2.59
Common Stock Reserved for Future Issuance	Common stock reserved for future issuance consisted of the following at March 31, 2015:
	Common stock warrants outstanding		1,178,109
	Common stock options outstanding under the 2008 Plan		622,192
	Common stock options outstanding and reserved under the 2012		9,375,272
	Plan
	Total		11,175,573

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Future Minimum Rental Payments Required under Operating Leases that have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year	Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of March 31, 2015, are as follows (in thousands):
	Fiscal year ended March 31, 2016	$	1,138
	Fiscal year ended March 31, 2017		1,148
	Fiscal year ended March 31, 2018		1,134
	Fiscal year ended March 31, 2019		1,032
	Fiscal year ended March 31, 2020		1,062
	Thereafter		1,558
	Total	$	7,072

Licensing_Agreements_and_Resea1

Licensing Agreements and Research Contracts (Tables)	12 Months Ended
	Mar. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Capitalized License Fees	Capitalized license fees consisted of the following (in thousands):
		March 31,			March 31,
		2015			2014
	License fees	$	114		$	114
	Less accumulated amortization		(34	)		(25	)
	License fees, net	$	80		$	89

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Summary of Net Deferred Tax Assets	Significant components of the Company’s net deferred tax assets are as follows as of March 31, 2015 and 2014 (in thousands):
		March 31,			March 31,
		2015			2014
	Deferred tax assets:
	Net operating loss carry forwards	$	—		$	—
	Research and development credits		—			—
	Depreciation and amortization		(48	)		22
	Accrued expenses and reserves		826			280
	Stock compensation		3,462			1,941
	Other, net		6			1
	Total deferred tax assets		4,246			2,244
	Valuation allowance		(4,246	)		(2,244	)
		$	—		$	—

Description_of_Business_and_Su3

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	1 Months Ended	2 Months Ended	3 Months Ended		12 Months Ended			1 Months Ended	37 Months Ended	1 Months Ended				0 Months Ended			12 Months Ended
	Sep. 30, 2013	Aug. 31, 2011	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012	Aug. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Oct. 31, 2011	Dec. 31, 2010	Oct. 31, 2013	Mar. 16, 2012	Feb. 29, 2012	Feb. 08, 2012	Dec. 31, 2011	Nov. 30, 2011	Sep. 18, 2011
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Common stock, par value					$0.00	$0.00										$0.00
Common stock conversion basis					1 for 1 basis
Former security holders common stock voting interest					75.00%
Company's stockholders retained voting interest					25.00%
Proceeds from issuance of convertible notes payable		$740,000
Accrued interest							25,000
Cash transaction costs related to the Merger approximately					2,100,000
Accumulated deficit					122,295,000	92,213,000
Cash flow from operations			2,755,000	3,556,000	19,601,000	15,561,000	9,693,000
Restricted cash					78,800	78,800
Inventory					66,000	63,000
Estimated useful life of the fixed assets					The estimated useful lives of the fixed assets range between three and seven years.
Impairment of long-lived assets					0
Total revenue recognized from inception on the contract			215,000	120,000	571,000	379,000	1,197,000
Fee for additional research and development services	76,000				135,000
Total potential contract value					1,500,000
Revenue related to research contract			98,000	120,000	134,000	248,000	1,035,000
Revenue recognized under grants			117,000	0	123,000	131,000	162,000
Dilutive effect			0	0	0	0	0
Common stock equivalents excluded from computing diluted net loss per share			8,900,000	25,800,000	8,600,000	7,700,000	15,200,000
Private, Not-for-Profit Organization [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants					49,000	119,000		251,700
Nih Research Grants [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants			117,000	0	0	12,000	162,000		558,000
Nih Research Grant Two [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants					74,000					222,000
Third Party [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Fee for additional research and development services					40,000
Total potential contract value					1,405,000
Research and Development Services [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Deferred revenue related to collaborative research programs and research service agreements					259,000	17,000
Research and development services on a fixed-fee basis											1,365,000
Initial payment to company from agreement											239,000
Remaining payments expected to occur over											21 months
Maximum amendment extended period remaining for payment of additional research and development services					28 months
Revenue related to research contract			97,000	120,000	0	184,000	885,000
12 Month Research Contract Agreement [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Term of research contract agreement with third party												12 months
Research and development services on a fixed-fee basis												600,000
Total revenue recognized from inception on the contract					600,000		150,000
Research and Development Services Two [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Initial payment to company from agreement	7,000
Revenue related to research contract					69,000	7,000
Research and Development Services Three [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Initial payment to company from agreement													29,000
Revenue related to research contract					41,000	52,000
Maximum [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Maturity of highly liquid investment					90 days
Useful life of fixed assets, range					7 years
Maximum [Member] | Research and Development Services Two [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Research and development services on a fixed-fee basis	83,000
Maximum [Member] | Research and Development Services Three [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Research and development services on a fixed-fee basis													93,000
Minimum [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Useful life of fixed assets, range					3 years
Minimum [Member] | Research and Development Services Two [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Research and development services on a fixed-fee basis	7,000
Minimum [Member] | Research and Development Services Three [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Research and development services on a fixed-fee basis													59,000
Convertible Notes Payable [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Convertible notes, interest rate		20.00%															10.00%	6.00%	6.00%
Merger Transition [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Number of private placement transactions					3
Total gross proceeds of approximately														6,900,000	1,800,000	5,000,000
Proceeds from issuance of convertible notes payable																	1,500,000
Accrued interest																$25,387
Merger Transition [Member] | Outstanding Principal Assumed On Acquisition [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Convertible notes converted into shares of common stock																	1,500,000
Merger Transition [Member] | Accrued Interest Assumed On Acquisition [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Convertible notes converted into shares of common stock																25,387
Predecessor
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Common stock, par value					$0.00

Description_of_Business_and_Su4

Description of Business and Summary of Significant Accounting Policies - Estimated Fair Values of Liabilities Measured on Recurring Basis (Detail) (Warrants [Member], USD $)	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability	$126	$377
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability	0	0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability	0	0
Significant Other Unobservable Inputs (Level 3) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability	126	377	6,898
Significant Other Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability	$126	$377

Description_of_Business_and_Su5

Description of Business and Summary of Significant Accounting Policies - Activity for Liabilities Measured at Estimated Fair Value Using Unobservable Inputs (Detail) (Significant Other Unobservable Inputs (Level 3) [Member], Warrants [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Significant Other Unobservable Inputs (Level 3) [Member] | Warrants [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Warrant Derivative Liability, Beginning balance	$377	$6,898
Issuances	0	0
Adjustments to estimated fair value	-196	5,120
Warrant liability removal due to settlements	-55	-10,874
Warrant liability reclassified to equity		-767
Warrant Derivative Liability, Ending balance	$126	$377

Fixed_Assets_Schedule_of_Fixed

Fixed Assets - Schedule of Fixed Assets (Detail) (USD $)	Mar. 31, 2015	Mar. 31, 2014
In Thousands, unless otherwise specified
Property Plant And Equipment [Abstract]
Laboratory equipment	$1,951	$1,207
Construction in process	529	0
Computer software and equipment	274	191
Furniture and fixtures	135	33
Leasehold improvements	155	0
Fixed assets, gross	3,044	1,431
Less accumulated depreciation and amortization	-1,002	-574
Fixed assets, net	$2,042	$857

Fixed_Assets_Additional_Inform

Fixed Assets - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012
Property Plant And Equipment [Abstract]
Depreciation and amortization expense	$78,000	$15,000	$464,000	$380,000	$188,000

Accrued_Expenses_Summary_of_Ac

Accrued Expenses - Summary of Accrued Expenses (Detail) (USD $)	Mar. 31, 2015	Mar. 31, 2014
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]
Accrued compensation	$1,917	$505
Accrued legal and professional fees	195	283
Other accrued expenses	145	34
Accrued expenses	$2,257	$822

Derivative_Liability_Additiona

Derivative Liability - Additional Information (Detail) (USD $)	1 Months Ended		3 Months Ended		12 Months Ended
	Nov. 30, 2013	Nov. 30, 2011	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012	Mar. 31, 2012	Dec. 31, 2011
								Private_placement
Derivative [Line Items]
Number of offerings under private placement reverse merger								3
Warrants maturity term	5 years	5 years						5 years
Estimated fair value of the outstanding warrant liabilities					$126,000	$377,000
Change in fair value of warrant liabilities			-12,034,000	-13,506,000	196,000	-5,120,000	-9,931,000	-9,931,000
Exercised derivative liabilities			6,990,556		8,647	1,920,874	13,010,237
Reclassification of warrant						269,657
Warrants [Member]
Derivative [Line Items]
Warrants issued		1,500,000						21,347,182
Fair value of the warrant liabilities				32,700,000				32,700,000	1,300,000
Estimated fair value of the outstanding warrant liabilities			$6,900,000		$100,000	$400,000	$20,600,000

Derivative_Liability_Assumptio

Derivative Liability - Assumptions Used to Value Derivative Liabilities at Closing Dates of Private Placements (Detail) (Warrant Derivative Liability [Member], USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Warrant Derivative Liability [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Closing price per share of common stock	$3.54	$7.64
Exercise price per share	$1	$1
Expected volatility	76.80%	76.50%
Risk-free interest rate	0.56%	0.90%
Dividend yield	0.00%	0.00%
Remaining expected term of underlying securities (years)	1 year 11 months 16 days	2 years 11 months 16 days

Convertible_Notes_Payable_Addi

Convertible Notes Payable - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

2 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

Sep. 18, 2011

Oct. 31, 2011

Nov. 30, 2011

Aug. 31, 2011

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2015

Mar. 31, 2014

Dec. 31, 2012

Dec. 31, 2011

Feb. 29, 2012

Nov. 30, 2014

Nov. 30, 2013

Private_placement

Investment

Debt Instrument [Line Items]

Funds raised through loans consisting of Convertible notes

$740,000

Warrant Discount

583,700

Purchase shares of common stock for issued warrants

21,347,182

2,909,750

Warrants expiration period

5 years

Warrants exercisable price, per share

$1

$1

$1

Expiration of warrant

5 years

Five-year warrants to purchase shares

1,500,000

Amortization of debt discount

0

896,000

0

0

896,200

Private placement securities per unit price

1

Number of common shares included in each unit

1

Number of warrants included in each unit

1

Closings under the private placement

3

Proceeds under Private Placement, total gross

13,722,600

Proceeds under Private Placement, total net

11,593,066

Total cash commissions paid to placement agent and selected dealers

1,372,260

Expense allowance paid to placement agent

411,678

Issued warrants to placement agent for purchase of common stock

6,099,195

Derivative liabilities estimated at fair value

32,742,000

Derivative liabilities exceeded the proceeds, amount

19,019,400

Interest expense

65,000

1,088,000

1,000

13,000

1,088,000

Private Placement [Member]

Debt Instrument [Line Items]

Purchase shares of common stock for issued warrants

610,155

Warrants exercisable price, per share

1

$1

Private placement offering, number of units of securities

30

Private placement offering, price per unit

50,000

Private placement offering, aggregate purchase price

1,500,000

Each unit consisted of a convertible note in the principal amount

50,000

Each unit consisted of a convertible note in the principal shares

50,000

Period of warrants

5 years

Payment to Private placement agent

195,000

Exercise price of warrants, per share

$1

Purchase of share of its Common Stock

15,247,987

Share issued for warrant

1,525,387

Common Stock [Member]

Debt Instrument [Line Items]

Common stock issued for conversion

7,676,828

Common Stock [Member] | Private Placement [Member]

Debt Instrument [Line Items]

Shares of Common Stock and warrants issued

13,722,600

Warrants [Member]

Debt Instrument [Line Items]

Purchase shares of common stock for issued warrants

1,309,750

Warrants exercisable price, per share

$6.84

$7.36

Interest rate

1.11%

Expected volatility

110.13%

Dividend yield

0.00%

Minimum [Member]

Debt Instrument [Line Items]

Warrants exercisable price, per share

$0.85

Minimum [Member] | Warrants [Member]

Debt Instrument [Line Items]

Warrants exercisable price, per share

$1.70

Maximum [Member]

Debt Instrument [Line Items]

Warrants exercisable price, per share

$7.36

Private placement offering, number of units of securities

16,000,000

Private placement offering, number of units of securities issued

8,000,000

Maximum [Member] | Warrants [Member]

Debt Instrument [Line Items]

Warrants exercisable price, per share

$3.24

Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible notes, interest rate

6.00%

6.00%

20.00%

10.00%

Percentage of per share fair market value of total consideration

75.00%

Convertible Notes principal balance

3,030,000

Accrued interest converted

459,800

Warrants classified as equity instruments

527,600

Unsecured Convertible Note, outstanding

100,000

Convertible note and accrued interest repaid

110,000

Convertible Notes issued

1,500,000

Expiration of warrant

5 years

Notes converted

1,525,387

Debt discount

1,260,300

Convertible Notes Payable [Member] | Warrants [Member]

Debt Instrument [Line Items]

Issuance of notes, recorded discount for beneficial conversion feature

$239,700

Convertible Notes Payable [Member] | Minimum [Member]

Debt Instrument [Line Items]

Accrued interest converted price range

$0.27

Convertible Notes Payable [Member] | Maximum [Member]

Debt Instrument [Line Items]

Accrued interest converted price range

$0.75

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended		3 Months Ended		12 Months Ended	1 Months Ended
	Aug. 02, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Nov. 30, 2013	Dec. 31, 2014	Feb. 27, 2015	31-May-08	Aug. 31, 2013	Jan. 31, 2012	Jul. 17, 2013
Class Of Stock [Line Items]
Shares authorized under shelf registration statement		150,000,000	150,000,000
Issuance of common stock		81,536,724	78,113,639
Offering price per share	$4.50
Proceeds from issuance of common stock	$43,400,000
Underwriting discounts and commissions and other offering expenses	3,200,000
Issuance of common stock from stock options exercises, net, Shares		205,033	183,796
Issuance of common stock from warrant exercises, net, Shares		210,600	2,713,207
Warrants exercised		211,647	3,201,633
Stock option exercised		205,684	183,796
Restricted stock awards issued to member of senior management		200,000
Research and development expense [Member]
Class Of Stock [Line Items]
Total employee stock-based compensation recorded as operating expenses		15,000	16,000	4,000	0	23,000
General and administrative expense [Member]
Class Of Stock [Line Items]
Total employee stock-based compensation recorded as operating expenses		406,000	801,000	474,000	0	812,000
Restricted stock [Member]
Class Of Stock [Line Items]
Restricted stock awards vested during the period		262,245	472,247	221,302		1,233,409
Restricted stock surrendered				24,690		89,674
Common stock returned by holders				10,000		95,842
Restricted stock awards granted		0	60,000	55,000		1,380,000
Total employee stock-based compensation recorded as operating expenses		421,000	817,000	478,000	0	835,000
Unrecognized restricted stock-based compensation expense		222,000
Total unrecognized compensation cost related, weighted average period		7 months 13 days
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Restricted stock awards vested during the period		255,000	405,000	50,000		211,250
Restricted stock surrendered		137,816	218,655
Stock option granted with immediate vesting		137,816	218,655	24,690		89,674
Percentage of vesting schedule						25.00%
Period for vesting schedule over start date						4 years
Senior Management [Member]
Class Of Stock [Line Items]
Restricted stock awards vested during the period		150,000
Restricted stock surrendered		50,000
Senior Management [Member] | Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Restricted stock awards granted						950,000
Non-Executive Employees [Member] | Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Restricted stock awards granted						130,000
Consultants [Member] | Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Restricted stock awards granted			60,000	55,000		100,000
Percentage of vesting schedule						100.00%
Period for vesting schedule over start date						6 months
Equity Distribution Agreement [Member]
Class Of Stock [Line Items]
Value of shares sold under equity distribution agreement		16,100,000	3,500,000
Issuance of common stock from stock options exercises, net, Shares		2,197,768	334,412
Equity Offering Sales Agreement [Member]
Class Of Stock [Line Items]
Value of shares sold under equity distribution agreement		6,200,000
Issuance of common stock from stock options exercises, net, Shares		1,000,000
Maximum [Member] | Equity Distribution Agreement [Member]
Class Of Stock [Line Items]
Number of shares to be offered and sold in equity distribution agreement							4,000,000
Securities authorized for offer and sale, amount								26,777,785
Underwriting Agreement [Member]
Class Of Stock [Line Items]
Securities authorized for offer and sale, amount									$190,000,000
Equity Incentive Plan 2008 [Member]
Class Of Stock [Line Items]
Common shares authorized to be issued										1,521,584
Termination date of Equity Incentive Plan		1-Jul-18
Shares issued during the year		0
Equity Incentive Plan 2012 [Member]
Class Of Stock [Line Items]
Common shares authorized to be issued											5,000,000	6,553,986
Shares available for issuance											11,553,986
Termination period of Equity Incentive Plan		10 years
IPO [Member]
Class Of Stock [Line Items]
Shares authorized under shelf registration statement													100,000,000
Issuance of common stock	10,350,000
Offering price per share	$4.23
Overallotment Option Exercised [Member] | Underwriting Agreement [Member]
Class Of Stock [Line Items]
Issuance of common stock	1,350,000

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Company's Restricted Stock Award Activity (Detail) (Restricted stock [Member])	3 Months Ended	12 Months Ended
	Mar. 31, 2013	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012
Restricted stock [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares	1,162,044	573,495	985,742	1,111,295
Granted, Number of Shares	55,000	0	60,000	1,380,000
Vested, Number of Shares	-221,302	-262,245	-472,247	-1,233,409
Canceled / forfeited, Number of Shares	-10,000	-52,500	0	-95,842
Ending balance, Unvested, Number of Shares	985,742	258,750	573,495	1,162,044

Stockholders_Equity_Additional1

Stockholders' Equity - Additional Information 1 (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012
Class Of Stock [Line Items]
Issuances of common stock from stock option exercises, Shares			205,684	183,796
Weighted-average remaining contractual term of options exercisable			7 years 9 months 26 days
Weighted-average remaining contractual term of options outstanding			8 years 3 months 11 days
Total unrecognized compensation cost related to unvested stock option grants			$15,115,000
Research and development expense [Member]
Class Of Stock [Line Items]
Total employee stock-based compensation recorded as operating expenses	4,000	0	15,000	16,000	23,000
General and administrative expense [Member]
Class Of Stock [Line Items]
Total employee stock-based compensation recorded as operating expenses	474,000	0	406,000	801,000	812,000
Stock options [Member]
Class Of Stock [Line Items]
Total employee stock-based compensation recorded as operating expenses	370,000	4,000	6,599,000	3,783,000	600,000
Total unrecognized compensation cost related, weighted average period			2 years 9 months 7 days
Stock options [Member] | Research and development expense [Member]
Class Of Stock [Line Items]
Total employee stock-based compensation recorded as operating expenses	58,000		1,175,000	462,000	81,000
Stock options [Member] | General and administrative expense [Member]
Class Of Stock [Line Items]
Total employee stock-based compensation recorded as operating expenses	$312,000	$4,000	$5,424,000	$3,321,000	$519,000
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Stock option granted with immediate vesting	24,690		137,816	218,655	89,674
2012 Plan [Member]
Class Of Stock [Line Items]
Issuances of common stock from stock option exercises, Shares			1,429,191	2,519,572
Remaining options vest			36 months
Stock option granted, restricted portion			56,500	99,500
2012 Plan [Member] | Stock options [Member]
Class Of Stock [Line Items]
Restricted stock vesting conditions			stock options generally vest on the one year anniversary of the grant date, quarterly over a three year period, or over a four-year period, with a quarter vesting on either the one year anniversary of employment or the one year anniversary of the vesting commencement date
2012 Plan [Member] | Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Stock option granted with immediate vesting			139,316	218,655
One Year Vesting [Member] | 2012 Plan [Member]
Class Of Stock [Line Items]
Stock option granted, restricted portion			128,500	122,500

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Outstanding, Beginning balance	5,935,888	3,618,567
Granted, Options Outstanding	1,429,191	2,519,572
Canceled, Options Outstanding	-45,847	-18,455
Exercised, Options Outstanding	-205,684	-183,796
Options Outstanding, Ending balance	7,113,548	5,935,888
Vested and Exercisable, Options Outstanding	3,113,164
Weighted-Average Exercise Price, Options Beginning balance	$4.87	$2.11
Options granted, Weighted-Average Exercise Price	$6.18	$8.63
Options canceled, Weighted-Average Exercise Price	$7.17	$3.31
Options exercised, Weighted-Average Exercise Price	$1.73	$2.19
Weighted-Average Exercise Price, Options Ending balance	$5.21	$4.87
Vested and Exercisable, Weighted-Average Exercise Price	$4.05
Aggregate Intrinsic Value, Options Beginning balance	$20,482,823	$5,909,154
Options Exercised, Aggregate Intrinsic Value	883,795	1,002,419
Aggregate Intrinsic Value, Options Ending balance	4,969,499	20,482,823
Vested and Exercisable at March 31, 2015	$3,264,723

Stockholders_Equity_Fair_Value

Stockholders' Equity - Fair Value of Employee Stock Options (Detail) (USD $)	1 Months Ended		12 Months Ended
	Nov. 30, 2014	Nov. 30, 2013	Mar. 31, 2015	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Dividend yield			0.00%	0.00%
Volatility	76.78%	96.90%	76.90%	78.22%
Risk-free interest rate	1.37%	0.60%	1.60%	1.32%
Expected life of options			6 years	6 years
Weighted average grant date fair value			$4.14	$5.92

Stockholders_Equity_Additional2

Stockholders' Equity - Additional Information 2 (Detail) (USD $)	1 Months Ended				3 Months Ended		12 Months Ended				0 Months Ended
	Nov. 30, 2014	Sep. 30, 2014	Nov. 30, 2013	Nov. 30, 2011	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012	Mar. 31, 2012	Dec. 21, 2012	Dec. 31, 2011	Oct. 31, 2011
									Agreement
Class Of Stock [Line Items]
Purchase shares of common stock for issued warrants									21,347,182			2,909,750
Proceeds From Warrant Exercises					$23,869,000		$55,000	$10,874,000	$23,321,000
Warrants exercisable price, per share									$1			$1	$1
Gross proceeds of warrants tendered									32,743,000
Exercised derivative liabilities					6,990,556		8,647	1,920,874	13,010,237
Warrants to purchase common stock	145,000		75,000						650,000
Interest expense					65,000	1,088,000	1,000	13,000	1,088,000
Number of agreement with consultants									4
Warrants maturity term			5 years	5 years						5 years
Volatility	76.78%		96.90%				76.90%	78.22%
Risk-free interest rate	1.37%		0.60%				1.60%	1.32%
Recognized expenses of warrants							43,000	163,000
Warrants earned, service period			12 months
Common Stock Warrants Issued		50,000
Weighted-average remaining contractual term of options exercisable							7 years 9 months 26 days
Preferred stock, shares authorized							25,000,000
Preferred stock, shares outstanding							0
Consultation Service Agreement September 2014
Class Of Stock [Line Items]
Recognized expenses of warrants							237,000
Consultation Service Agreement November 2014
Class Of Stock [Line Items]
Recognized expenses of warrants							36,000
Minimum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share							$0.85
Warrants maturity term									2 years
Maximum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share							$7.36
Warrants maturity term									5 years
Tender offer [Member]
Class Of Stock [Line Items]
Outstanding warrants to purchase											14,500,000
Warrants exercisable price, per share											$1
Exercise price of warrant Amended											$0.80
Warrant proceeds											9,600,000
Gross proceeds of warrants tendered											7,700,000
Recognized expenses of warrants											1,900,000
Costs incurred related to warrant exercises											400,000
Amendment March 2014 [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share								$1
Warrants to purchase common stock								269,657
Amendment March 2014 [Member] | Minimum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share								$0.85
Warrants [Member]
Class Of Stock [Line Items]
Purchase shares of common stock for issued warrants													1,309,750
Number Of Warrants Exercised							203,000	225,000
Proceeds From Warrant Exercises							445,000	210,000
Number of warrant exercised through cashless							8,647	2,628,003
Cashless exercise for issuance of common stock							7,600	2,139,577
Warrants exercisable price, per share	6.84		7.36
Estimated fair value of warrants	309,000		404,000						890,000
Recognized expenses of warrants							0	72,000
Weighted-average remaining contractual term of options exercisable							2 years 4 months 17 days
Warrants [Member] | Consultants [Member]
Class Of Stock [Line Items]
Number Of Warrants Exercised							0	348,630
Proceeds From Warrant Exercises								891,000
Warrants [Member] | Minimum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share									$1.70
Volatility									79.80%
Risk-free interest rate									0.24%
Warrants [Member] | Maximum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share									$3.24
Volatility									103.80%
Risk-free interest rate									0.63%
Warrants [Member] | Amendment March 2014 [Member]
Class Of Stock [Line Items]
Interest expense								$12,000

Stockholders_Equity_Summary_of2

Stockholders' Equity - Summary of Warrant Activity (Detail) (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance	5,935,888	3,618,567
Granted, Options Outstanding	1,429,191	2,519,572
Expired / Canceled, Options Outstanding	45,847	18,455
Exercised, Options Outstanding	-205,684	-183,796
Options Outstanding, Ending balance	7,113,548	5,935,888
Weighted-Average Exercise Price, Options Beginning balance	$4.87	$2.11
Granted, Weighted-Average Exercise Price	$6.18	$8.63
Options canceled, Weighted-Average Exercise Price	$7.17	$3.31
Exercised, Weighted-Average Exercise Price	$1.73	$2.19
Weighted-Average Exercise Price, Options Ending balance	$5.21	$4.87
Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance	1,194,756	4,283,889
Granted, Options Outstanding	195,000	112,500
Expired / Canceled, Options Outstanding	0	0
Exercised, Options Outstanding	-211,647	-3,201,633
Options Outstanding, Ending balance	1,178,109	1,194,756
Weighted-Average Exercise Price, Options Beginning balance	$1.79	$1.17
Granted, Weighted-Average Exercise Price	$7.04	$7.36
Options canceled, Weighted-Average Exercise Price	$0	$0
Exercised, Weighted-Average Exercise Price	$2.14	$1.16
Weighted-Average Exercise Price, Options Ending balance	$2.59	$1.79

Stockholders_Equity_Common_Sto

Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail)	Mar. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	11,175,573
Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	1,178,109
Stock options [Member] | Equity Incentive Plan 2008 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	622,192
Stock options [Member] | Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	9,375,272

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended		3 Months Ended		12 Months Ended
	Jan. 09, 2015	Dec. 05, 2013	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012	Mar. 12, 2015
	sqft	sqft						sqft
Commitments And Contingencies Disclosure [Abstract]
Leasehold improvements					$144,000
Rent expense			105,500	60,200	968,000	561,500	325,600
Base rent under the lease	12,000	38,800			38,800
Base rent escalators	3.00%	3.00%			3.00%
Lease term with option to extend					48 months
Increased office space size		15,268						335
Area of leased office space	5,803	15,539
Total office space under lease agreement		30,807
Lease expiration date		1-Aug-16
Rent expense per month		$38,934
Additional office space		14,500
Expansion premises commencement date					1-Sep-14
Increase of net adjustment leased space								88
Lease term	36 months
Lease rental period start date	1-Feb-15
Lease rental period end date	31-Jan-18

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Rental Payments Required under Operating Leases that have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year (Detail) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]
Fiscal year ended March 31, 2016	$1,138
Fiscal year ended March 31, 2017	1,148
Fiscal year ended March 31, 2018	1,134
Fiscal year ended March 31, 2019	1,032
Fiscal year ended March 31, 2020	1,062
Thereafter	1,558
Total	$7,072

Licensing_Agreements_and_Resea2

Licensing Agreements and Research Contracts - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended			0 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012	Mar. 12, 2010	Mar. 24, 2009	2-May-11	Feb. 28, 2013
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Other assets amortized			$80,000	$89,000
Amortization expense of licenses	2,000	1,700	8,500	8,500	7,000
Weighted average remaining amortization period for all licenses			10 years
Annual amortization expense of licenses year 1			8,500
Annual amortization expense of licenses year 2			8,500
Annual amortization expense of licenses year 3			8,500
Annual amortization expense of licenses year 4			8,500
Annual amortization expense of licenses year 5			8,500
University of Missouri [Member]
Finite-Lived Intangible Assets [Line Items]
License cost						5,000	25,000
Royalty fees percentage minimum						1.00%	1.00%
Royalty fees percentage maximum						3.00%	3.00%
Annual royalty						5,000	25,000
Expected expiration year of license agreement							2029
Other assets amortized						5,000	25,000
Prior patent costs relating to the license agreements	0		0	0	193,500
Clemson University [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty payment			40,000
Annual royalty payment due				20,000
Clemson University [Member] | Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
License cost								32,500
Royalty fees percentage minimum								1.50%
Royalty fees percentage maximum								3.00%
Additional license fee to reimburse future patent costs								32,500
Expected expiration year of license agreement								2024-05
Clemson University [Member] | Other Assets [Member] | Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Other assets amortized								65,000
Clemson University [Member] | Minimum [Member] | Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Annual royalty								20,000
Clemson University [Member] | Maximum [Member] | Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Annual royalty								40,000
Becton Dickinson [Member]
Finite-Lived Intangible Assets [Line Items]
Payments to purchase exclusive rights to intellectual property									$18,500

Licensing_Agreements_and_Resea3

Licensing Agreements and Research Contracts - Schedule of Capitalized License Fees (Detail) (Licensing Agreements [Member], USD $)	Mar. 31, 2015	Mar. 31, 2014
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
License fees	$114,000	$114,000
Less accumulated amortization	-34,000	-25,000
License fees, net	$80,000	$89,000

Income_Taxes_Summary_of_Net_De

Income Taxes - Summary of Net Deferred Tax Assets (Detail) (USD $)	Mar. 31, 2015	Mar. 31, 2014
In Thousands, unless otherwise specified
Deferred tax assets:
Net operating loss carry forwards	$0	$0
Research and development credits	0	0
Depreciation and amortization	-48	22
Accrued expenses and reserves	826	280
Stock compensation	3,462	1,941
Other, net	6	1
Total deferred tax assets	4,246	2,244
Valuation allowance	-4,246	-2,244
Deferred tax assets net	$0	$0

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating Loss Carryforwards [Line Items]
Unrecognized tax benefits	$0
Increase (decrease) in valuation allowance	2,002,000	1,277,000
Federal net operating loss carryforwards	59,334,000
State net operating loss carryforwards	58,850,000
Federal and state net operating loss carryforwards expiring year	2028
Net operating loss carryforwards related to windfall tax benefits	6,236,000
Federal research tax credit carryforwards expiration period	2028
Accrued expense regarding interest or penalties	0
Federal [Member]
Operating Loss Carryforwards [Line Items]
Research tax credit carryforwards	790,000
State [Member]
Operating Loss Carryforwards [Line Items]
Research tax credit carryforwards	$987,000

Defined_Benefit_Plan_Additiona

Defined Benefit Plan - Additional Information (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Defined Benefit Pension Plans And Defined Benefit Postretirement Plans Disclosure [Abstract]
Percentage of employees contribution	6.00%
Administration expenses	$57,000	$0